The DOI matches its Crossref record; 867 of the 881 references it cites were found in a registry or an index, and 14 are not checked yet; none of the 655 sources its claims cite is checked for support yet.
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Open accessAbstract
nine societies and by invited experts)
Checked 2026-10-05 · 14 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 655 cited sources checked · 0 supported · 0 flagged
In the paper
“When these were evaluated using the Appraisal of Guidelines Research and Evaluation (AGREE) instrument, only seven achieved the level considered 'considerable rigour'.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.1 Introduction
What the sources say
- Not checked yetcites [4] Ferket, 2010, Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check?, Arch Intern Med source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In many MONICA centres there were quite substantial changes, up or down, in CVD events within time periods as small as 10 years.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [16] Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“The relationship between changes in risk factor scores and changes in event rates was substantial.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [16] Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Moreover, there was a significant association between treatment change and case fatality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [16] Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“On the other hand, lipid control has improved significantly. 5”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
What the sources say
- Not checked yetcites [5] Kotseva, 2009, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“the results from the hospital arm of EUROASPIRE III 33 (2006-2007) in 8966 patients with established CHD from 22 European countries show that large proportions of patients still do not achieve the lifestyles, risk factor levels, and therapeutic targets set in 2003 by the third JTF.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
What the sources say
- Not checked yetcites [33] Kotseva, 2009, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“An examination of the Framingham estimates of risk of total CVD events results in similar conclusions: a 5% SCORE risk of CVD death equates to a 10 -25% Framingham risk of total CVD, depending upon which of the several Framingham functions is chosen.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Table 5 shows that a person with a cholesterol concentration of 8 mmol/L (310 mg/dL) can be at 10 times lower risk than someone with a cholesterol concentration of 5 mmol/L (190 mg/dL) if the latter is a male hypertensive smoker.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.2 Strategies
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“The efficacy and safety of such programmes have been demonstrated in the EURO-ACTION project-an ESC demonstration project showing that the recommended lifestyle changes and the targeted management of cardiovascular risk factors are achievable and sustainable in daily clinical practice, in both primary and secondary care.35”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
What the sources say
- Not checked yetcites [35] Wood, 2008, Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In some age categories the majority, especially of men, will have estimated cardiovascular death risks exceeding the 5 -10% level, based on age (and gender) only, even when other cardiovascular risk factor levels are relatively low.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 100
- It may state two separate claims as one. 237
- The quote only partly states this claim. 1
In the paper
“of all deaths that occur before the age of 75 years in Europe, 42% are due to CVD in women and 38% in men.”
- Also stated in: § 2.1 Scope of the problem · plain
“CVD was responsible for 42% of all deaths below 75 years of age in European women and for 38% of all deaths at ,75 years in men.14”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [14] European Heart Network, 2008
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § 2.1 Scope of the problem · plain
In the paper
“Beneficial reductions in major risk factors-in particular smoking, BP, and cholesterol-accounted for more than half of the decrease in CHD deaths, although they were counteracted by an increase in the prevalence of obesity and type 2 diabetes; 40% of the decline in CHD death rates is attributed to better treatments of acute myocardial infarction, heart failure, and other cardiac conditions.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [29] Ford, 2007, deaths from coronary disease, 1980–2000, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“and the changes in risk factors explained almost half the variation in event rates in men but less in women.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [16] Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The figure shows that the effect of the lipid levels on risk is modest in women who are at otherwise low risk, and that the risk advantage of being female is lost by the combination of smoking and mild hypertension.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.2 Strategies
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Moreover, the changes between EUROASPIRE I (1996) and EUROASPIRE III reveal that the proportion of smokers did not change and BP control has not improved despite increased use of antihypertensive drugs, while the number of patients with (central) obesity continues to increase.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
What the sources say
- Not checked yetcites [5] Kotseva, 2009, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Fasting triglycerides relate to risk in univariate analyses, but the effect is attenuated by adjustment for other factors, especially HDL cholesterol.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The fact that CVD mortality has declined in many European countries means that more countries now fall into the low-risk category.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Cardiovascular risk age
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“While there is heterogeneity between cohorts, overall, the impact of diabetes on risk appears greater than in risk estimation systems based on the Framingham cohort, with relative risks of 5 in women and 3 in men.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Five years later, when he reaches 50 years, his risk increases into the danger zone of 14% over 10 years and he requires treatment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In the US Women's Health Initiative, only 4% of women fell into this ideal state and a further 13% had no risk factors but failed to follow a healthy lifestyle.83”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [83] Hsia, 2010, Evaluation of the American Heart Association cardiovascular disease prevention guideline for women, Circ Cardiovasc Qual Outcomes source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Conflicts, crises, and long-term stressful conditions in family life have also been shown to increase CHD risk [hazard ratio (HR) 2.7 -4.0], especially in women (RR 2.9 -4.0).96,97”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [96] Eaker, 2007, Marital status, marital strain, and risk of coronary heart disease or total mortality: the Framingham Offspring Study, Psychosom Med source
- Not checked yetcites [97] Orth-Gomer, 2000, Marital stress worsens prognosis in women with coronary heart disease: the Stockholm Female Coronary Risk Study, JAMA source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Perceived social support seems to counteract the adverse effect of depression, 103 whereas lack of support was found to reinforce its adverse effects.104”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [103] Frasure-Smith, 2000, Social support, depression, mortality during the first year after myocardial infarction, Circulation source
- Not checked yetcites [104] Horsten, 2000, Depressive symptoms and lack of social integration in relation to prognosis of CHD in middle-aged women. The Stockholm Female Coronary Risk Study, Eur Heart J source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several systematic reviews and meta-analyses have shown that clinical depression and depressive symptoms predict incident CHD (RR 1.6 and 1.9), 98 -100 and worsen its prognosis (OR 1.6 and 2.4). 100 -102”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [98] Rugulies, 2002, Depression as a predictor for coronary heart disease. a review and meta-analysis, Am J Prev Med source
- Not checked yetcites [99] Wulsin, 2003, Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review, Psychosom Med source
- Not checked yetcites [100] Nicholson, 2006, Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies, Eur Heart J source
- Not checked yetcites [101] Barth, 2004, Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis, Psychosom Med source
- Not checked yetcites [102] van Melle, 2004, Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis, Psychosom Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“CVD is the major cause of death in women in all European countries; below 75 years, 42% of women die from CVD compared with 38% of men.14”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [14] European Heart Network, 2008
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, two recent meta-analyses confirmed that anxiety is an independent risk factor for incident CHD (HR 1.3) 111 and for adverse events following myocardial infarction (OR 1.5 and 1.7, respectively).112”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [111] Roest, 2010, Anxiety and risk of incident coronary heart disease: a meta-analysis, J Am Coll Cardiol source
- Not checked yetcites [112] Roest, 2010, Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis, Psychosom Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There is limited evidence that routine screening for psychosocial risk factors contributes to fewer future cardiac events, as screening has not yet translated into improved healthcare models.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Remaining gaps in the evidence
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent meta-analyses have shown that symptoms of anxiety and the type D personality increase risk for CVD and contribute to worse clinical outcome.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.4.3 Assessment of psychosocial risk factors
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The magnitude of effect on risk is modest, and consistency is often lacking, mainly due to nutritional, metabolic (e.g.renal disease), and lifestyle confounders.128”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.5.2 Thrombotic Homocysteine
What the sources say
- Not checked yetcites [128] Clarke, 2010, Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Similar statements are made for fibrinogen.127”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > III B Strong 128
What the sources say
- Not checked yetcites [127] Kaptoge, 2007, Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration, Am J Epidemiol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Simplification of treatment improves adherence to therapy”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“calcium antagonists, besides being effective in LVH, appear particularly beneficial in slowing down progression of carotid hypertrophy and atherosclerosis.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“thiazide and thiazide-like diuretics (chlorthalidone and indapamide), betablockers, calcium antagonists, ACE inhibitors, and angiotensin receptor antagonists can adequately lower BP, and significantly reduce risk of cardiovascular morbidity and mortality”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Aliskiren, which inhibits the effect of renin and pro-renin on their specific receptors, effectively lowers BP in hypertension 427 and has an antiproteinuric effect.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
What the sources say
- Not checked yetcites [427] Gradman, 2005, Aliskiren, a novel orally effective renin inhibitor provides dose-dependent antihypertensive efficacy placebo-like tolerability in hypertensive patients, Circulation source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“this may not apply to vasodilating beta-blockers such as carvedilol and nebivolol, which have less or no dysmetabolic action, as well as a reduced incidence of new-onset diabetes compared with conventional beta-blockers.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“they are also quite effective in reducing microalbuminuria and proteinuria and in preserving renal function and delaying end-stage renal disease”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“as beta-blockers induce weight gain, have adverse effects on lipid metabolism, 395 and increase (compared with other drugs) the incidence of new-onset diabetes”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
What the sources say
- Not checked yetcites [395] Poulter, 2005, Role of blood pressure other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Alpha 1 -blockers, centrally acting agents [alpa 2adrenoreceptor agonists and imidazoline (I 1 ) receptor agonists], and antialdosterone drugs effectively lower BP.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hypertension is more common in patients with type 2 diabetes compared with the general population.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.6 Blood pressure
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“There was no significant difference between groups for any of the individual composites of the primary outcome or for all-cause mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
What the sources say
- Not checked yetcites [438] Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
In the paper
“The trial was stopped prematurely at 3.5 years due to a significantly increased total mortality in the intensive treatment group: 257 vs. 203 (P ¼ 0.04) for deaths due to any cause and 135 vs. 94 (P ¼ 0.02) for deaths due to cardiovascular causes.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
What the sources say
- Not checked yetcites [435] Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Post-trial monitoring of the UKPDS substudy showed no legacy effect (i.e.intensive BP control has to be maintained for continued benefit).426”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.6 Blood pressure
What the sources say
- Not checked yetcites [426] Holman, 2008, Long-term follow-up after tight control of blood pressure in type 2 diabetes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Weight gain and hypoglycaemia were less frequent than in the ACCORD study.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
What the sources say
- Not checked yetcites [435] Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“There were significantly more cases of hypoglycaemia requiring assistance in the intensive group, who also experienced significantly more weight gain.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
What the sources say
- Not checked yetcites [435] Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“There was a marked and significant 44% risk reduction for stroke and a non-significant 21% risk reduction for myocardial infarction associated with a 10 mmHg reduction in SBP and a 5 mmHg reduction in DBP.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.6 Blood pressure
What the sources say
- Not checked yetcites [441] UK Prospective Diabetes Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Post-hoc analyses of large-scale trials (e.g.ONTARGET, INVEST, and VALUE), although suffering from the limitation posed by comparisons of nonrandomized groups, suggest that at least in high-risk hypertensive patients, there may be no advantage or even harm in lowering systolic BP below 130 mmHg, except perhaps for stroke.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.4 Blood pressure goals
What the sources say
- Not checked yetcites ONTARGET
- Not checked yetcites INVEST
- Not checked yetcites VALUE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The intensive treatment group had a 17% relative risk reduction in diabetes-related death (P ¼ 0.01), a 15% reduction in risk of myocardial infarction (P ¼ 0.01), and a 13% reduction in risk of death from any cause (P ¼ 0.007).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.3 Glucose control
What the sources say
- Not checked yetcites [444] Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In the elderly, outcome trials have only addressed patients with an entry SBP ≥160 mmHg, and no trial achieved an average SBP ,140 mmHg.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.5 Hypertension in special conditions
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Meta-analyses of available trials show that, in diabetes, all major antihypertensive drug classes protect against cardiovascular complications, probably because of the protective effect of BP lowering per se.”
- Also stated in: § 4.8.6 Blood pressure · hedged
“Meta-analyses of available trials show that, in diabetes, all major antihypertensive drug classes protect against cardiovascular complications, probably because of the protective effect of BP lowering per se.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.5 Hypertension in special conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § 4.8.6 Blood pressure · hedged
In the paper
“post-hoc analyses of trial data indicate a progressive reduction in incidence of cardiovascular events with progressive lowering of SBP down to 120 mmHg and DBP down to 75 mmHg, 412 although the additional benefit at low BP values becomes rather small.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.4 Blood pressure goals
What the sources say
- Not checked yetcites [412] Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Intensive control significantly reduced the total number of major macrovascular events (death from cardiovascular causes, non-fatal myocardial infarction, nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), but only the reduction in microvascular events was statistically significant.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
What the sources say
- Not checked yetcites [435] Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A meta-analysis of intensive glucose control including data from UKPDS, Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive), ACCORD, ADVANCE, and VADT 447 showed a significant reduction in non-fatal myocardial infarction and CHD events, but no effect on stroke or total mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.5 Meta-analysis and systematic reviews
What the sources say
- Not checked yetcites [447] Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Intensive management of hyperglycaemia in diabetes reduces the risk of microvascular complications and, to a lesser extent, that of cardiovascular disease.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Important new information
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Aggressive control of hypertension and lowering cholesterol levels with statins reduce the risk of cardiovascular events”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.1 Introduction
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A more recent meta-analysis examined trials of intensive vs. conventional glycaemic control, but did not include PROactive, and again identified the UKPDS, ACCORD, ADVANCE, and VADT trials.449 Similar results were found with a significant reduction in CHD and CVD events, but no reduction in cardiovascular mortality or total mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.5 Meta-analysis and systematic reviews
What the sources say
- Not checked yetcites [449] Turnbull, 2009, Intensive glucose control and macrovascular outcomes in type 2 diabetes, Diabetologia source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The reactive treatment effect was independent of baseline cholesterol, although the absolute risk and treatment effect increased with rising cholesterol concentration.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.7 Dyslipidaemia
What the sources say
- Not checked yetcites [436] Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“There was no improvement in the primary endpoint, with slight reductions in the secondary endpoint of strokes, and an increase in side effects with a lower target.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.6 Blood pressure
What the sources say
- Not checked yetcites [451] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.9 Microalbuminuria and multifactorial intervention
What the sources say
- Not checked yetcites [455] Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Aspirin significantly reduced the risk of myocardial infarction in men, but not in women.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.8 Antithrombotic therapy
What the sources say
- Not checked yetcites [443] De Berardis, 2009, Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials, BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“apoB can be substituted for LDL cholesterol, 475 but it does not add further to the risk assessment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.3 Apolipoprotein B
What the sources say
- Not checked yetcites [475] Thompson, 2006, Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies, J Intern Med source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hypertriglyceridaemia and low HDL cholesterol are independent CVD risk factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9 Lipids Key messages
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
In the paper
“it appears that apoB is a similar risk marker to LDL cholesterol and a better index of the adequacy of LDL-lowering therapy.476”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.3 Apolipoprotein B
What the sources say
- Not checked yetcites [476] McQueen, 2008, Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In the HOT study, 75 mg of aspirin further reduced the risk of major cardiovascular events in well-controlled hypertensive patients with diabetes, but non-fatal major bleeds were significantly more common among patients receiving aspirin.440”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.8 Antithrombotic therapy
What the sources say
- Not checked yetcites [440] Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It remains the major cause of premature death in Europe, even though CVD mortality has fallen considerably over recent decades in many European countries.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.1 Introduction
What the sources say
- Not checked yetcites [14] European Heart Network, 2008
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“within the coming decades the disability-adjusted life years (DALYs) estimate is expected to rise from a loss of 85 million DALYs in 1990 to a loss of 150 million DALYs globally in 2020, thereby remaining the leading somatic cause of loss of productivity. 1”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.1 Introduction
What the sources say
- Not checked yetcites [1] SIGN (Scottish Intercollegiate Guidelines Network), 2007, Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The level of evidence and the strength of recommendation of particular treatment options were weighed and graded according to the ESC recommendations (Tables 1 and 2).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statements from the writing panel disclosing conflicts of interest are available on the ESC website.Changes in conflicts of interest that arose during the writing period were notified.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“and may also be used in conjunction with appraisals of resource use and cost-effectiveness.10”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [10] Guyatt, 2008, What is ‘quality of evidence’ and why is it important to clinicians?, BMJ source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The preparation and publication of the fifth JTF report was supported financially by the ESC without any involvement of the pharmaceutical industry.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The concept of primary and secondary prevention was replaced by the recognition that atherosclerosis was a continuous process.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In short, experts from the nine organizations performed a comprehensive review and a critical evaluation of diagnostic and therapeutic procedures, including assessment of the risk-benefit ratio.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The JTF introduced GRADE as it uses a transparent and rigorous process to assess the quality of evidence in terms of whether further research would or would not change confidence in the estimate of intervention effects or diagnostic accuracy.10”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.4 Combining evaluation methods
What the sources say
- Not checked yetcites [10] Guyatt, 2008, What is ‘quality of evidence’ and why is it important to clinicians?, BMJ source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, as resources are valued differently across Europe, it is not feasible in these guidelines to make judgements about the appropriateness of resource use for the interventions and diagnostic strategies considered here.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Once the document had been finalized by the fifth JTF experts it was submitted for extensive independent external review.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“GRADE also distinguishes quality of evidence and strength of recommendation.9 Strong evidence does not automatically lead to a strong recommendation.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [9] Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence strength of recommendations, BMJ source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Rather than have a range of classes of recommendation (e.g.Class I-Class III), GRADE only uses two categories-strong or weak (i.e.discretionary, conditional).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [9] Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence strength of recommendations, BMJ source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Atherosclerotic CVD, especially CHD, remains the leading cause of premature death worldwide.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [11] Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“CVD mortality is changing, with declining age-standardized rates in most European countries, which remain high in Eastern Europe.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [15] Levi, 2009, Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update, Eur J Cardiovasc Prev Rehabil source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Following this revision and after acceptance by the ESC Committee for Practice Guidelines and the co-operating organizations in the fifth JTF, the document was published.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 1.2 Development of guidelines
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is very helpful in assessing evidence for CVD prevention where RCTs of health behaviours are difficult to conduct and may be misleading.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This model has been applied in different countries; the results from these studies are rather consistent and similar to what has been observed in other studies of the same subject, as summarized in Figure 1.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [29] Ford, 2007, deaths from coronary disease, 1980–2000, N Engl J Med source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The second major CVD-stroke-is another substantial cause of death and disability.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of these patients develop the disease at an advanced age, leading to a compression of morbidity in the very old of the community and to a prolonged life expectancy in good health.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Since the instruction by Geoffrey Rose decades ago, two approaches towards prevention of CVD are considered: the population strategy and the high-risk strategy.19”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
What the sources say
- Not checked yetcites [19] Rose, 1985, Sick individuals and sick populations, Int J Epidemiol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The only reasonable explanation is that both environmental changes, especially related to lifestyle, and improved management are important.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus it was concluded that both primary prevention and treatment of cardiovascular events influence mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although individuals targeted in this strategy are more likely to benefit from the preventive interventions, the impact on the population level is limited, because people at such high risk are few.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Prevention works: .50% of the reductions seen in CHD mortality relate to changes in risk factors, and 40% to improved treatments.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
What the sources say
- Not checked yetcites [29] Ford, 2007, deaths from coronary disease, 1980–2000, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Results from the Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) project indicated a heterogeneous trend in CHD incidence in the 1980s to 1990s in Europe.16”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
What the sources say
- Not checked yetcites [16] Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus a healthy lifestyle in the young is crucial, although ethical and other reasons prohibit the provision of strong levels of evidence based on randomized trials for the benefits in terms of reduced incidence of CVD from, for example, school programmes on health education or smoking cessation actions.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“'Coronary heart disease (CHD) is now the leading cause of death worldwide; it is on the rise and has become a true pandemic that respects no borders'.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
What the sources say
- Not checked yetcites [11] Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At present there is no standardized source of Europe-wide CVD morbidity data.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CVD prevention in the young, the very old, or those with just a moderate or mild risk is still limited, but can result in substantial benefit.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This pattern may have changed, and results from recent reports do suggest that mortality and morbidity from CHD is levelling, especially in younger adults.17,18”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
What the sources say
- Not checked yetcites [17] Ford, Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates, J Am Coll Cardiol 2007 source
- Not checked yetcites [18] Vander Stichele, 2008, Is the decline in coronary attack rates leveling off in Flanders?, Eur J Cardiovasc Prev Rehabil
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The advantage is that it may bring large benefits to the population although it may offer little to the individual.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite gaps in our understanding, there is ample evidence to justify intensive public health and individual preventive efforts.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Indirectness of evidence
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Although children are at very low absolute risk of developing CVD, those at a relatively high risk compared with their peers remain at increased risk of experiencing a cardiovascular event later in life because of 'tracking' of risk factors”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
What the sources say
- Not checked yetcites [23] Vos, 2003, Adolescent blood pressure and blood pressure tracking into young adulthood are related to subclinical atherosclerosis: the Atherosclerosis Risk in Young Adults (ARYA) study, Am J Hypertens source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“For a long time the population strategy has been considered to be more costeffective than the high-risk approach but since the introduction of highly effective lipid lowering drugs, improvement in smoking cessation programmes and lower costs of antihypertensive drugs, the effectiveness of the high risk approach has increased.20”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
What the sources say
- Not checked yetcites [20] Manuel, 2006, Revisiting Rose: strategies for reducing coronary heart disease, BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In Europe, the burden remains high: CVD remains a major cause of premature deaths and loss of DALYs-a composite of premature death and living with the disease.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.1 Scope of the problem
What the sources say
- Not checked yetcites [14] European Heart Network, 2008
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prevention is typically categorized as primary or secondary prevention, although in CVD the distinction between the two is arbitrary in view of the underlying, gradually developing atherosclerotic process.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.2 Prevention of cardiovascular disease: a lifelong approach
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Our understanding of the reasons for changes in the behaviour of both populations and individuals remains incomplete.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although clinicians often ask for threshold values at which to trigger an intervention, this is problematic since risk is a continuum and there is no exact point above which, for example, a drug is automatically indicated, nor below which lifestyle advice may not usefully be offered.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations regarding risk estimation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The choice of CVD mortality rather than total (fatal + nonfatal) events was deliberate although not universally popular.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“All risk estimation systems are relatively crude and require attention to qualifying statements.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As noted in the 'priorities' section, persons with established CVD are already at very high risk of further events and need prompt intervention on all risk factors”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients who have had a clinical event such as an acute coronary syndrome (ACS) or stroke automatically qualify for intensive risk factor evaluation and management.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Having said that, the implication that total risk assessment, while logical, is associated with improved clinical outcomes when compared with other strategies has not been adequately tested.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations regarding risk estimation
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The potential for prevention based on healthy lifestyles, appropriate management of classical risk factors, and selective use of cardioprotective drugs is obvious.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In younger persons, a low absolute risk may conceal a very high relative risk, and use of the relative risk chart or calculation of their 'risk age' may help in advising them of the need for intensive lifestyle efforts.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“and many committees from other countries have almost the same views.33”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.3 Prevention of cardiovascular disease pays off
What the sources say
- Not checked yetcites [33] Kotseva, 2009, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A risk estimation system such as SCORE can assist in making logical management decisions, and may help to avoid both under-and overtreatment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“The 2003 guidelines 44 used the SCORE chart for risk estimation, 45 which was based on data from 12 European cohort studies; it included 205 178 subjects examined at baseline between 1970 and 1988 with 2.7 million years of follow-up and 7934 cardiovascular deaths.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
What the sources say
- Not checked yetcites [45] Conroy, 2003, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, Eur Heart J source
Strength:plain· not yet calibratedn = 205,178Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The SCORE system estimates the 10-year risk of a first fatal atherosclerotic event, whether heart attack, stroke, aneurysm of the aorta, or other.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The multiplier to convert fatal to total CVD is similarly unstable and is often less than clinicians expect, since follow-up is terminated in all current systems with the first event, and subsequent fatal or non-fatal events are not counted.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Risk charts such as SCORE are intended to facilitate risk estimation in apparently healthy persons.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While women appear to be at lower CVD risk than men, this is misleading as risk is deferred by 10 years rather than avoided.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While the ideal scenario would be for all adults to have their risk of CVD assessed, this may not be practicable for many societies.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The term has become widely used; however, 'total risk' is not comprehensive because the effects of other risk factors are not considered except as qualifying statements.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.2 Strategies
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Any risk estimation system will overpredict in countries in which mortality has fallen and underpredict in those in which it has risen.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In general, women and old and young subjects have been underrepresented in the classic drug trials that have informed guidelines to date.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.2 Strategies
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most people will visit their family doctor at least once over a 2-year period giving an opportunity for risk assessment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The total risk approach allows flexibility: if perfection cannot be achieved with one risk factor, risk can still be reduced by trying harder with others.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the '20% total CVD (or CHD)' risk used to denote high risk in many guidelines is likely to be variable, unstable over time, and hard to validate.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additional factors affecting risk can be accommodated in electronic risk estimation systems such as HeartScore (www.heartscore.org).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As such, they acknowledge that individuals at the highest levels of risk gain most from risk factor management.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations regarding risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Certain individuals are at high CVD risk without needing risk scoring and require immediate intervention for all risk factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Death is a hard and reproducible endpoint; a non-fatal event is variable and depends upon definitions, diagnostic criteria, and diagnostic tests, all of which may vary over time.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most other systems estimate CHD risk only.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Striking changes in both diagnostic tests and therapies have occurred since the SCORE cohorts were assembled.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the fact that all elderly people will eventually be at high risk of death and may be overexposed to drug treatments.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations regarding risk estimation
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is uncertain whether CVD is merely deferred by preventive efforts or if it of can be avoided completely.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 2.4 Ample room for improvement
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For these reasons, the CVD mortality charts were produced, and have been re-calibrated for a number of European countries.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.1.3 Risk estimation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In SCORE, accounting for family history is probably very crude and is most certainly an underestimate.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.2 Genetics Key message
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Increasing age and male sex increase CVD risk and are 'fixed' characteristics used to stratify risk assessments.45”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.3 Age and gender
What the sources say
- Not checked yetcites [45] Conroy, 2003, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, Eur Heart J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Even the high-risk charts may underestimate risk in these countries.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Very-high-risk countries
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The higher the risk the greater the benefit from preventive efforts, which guides the following priorities:”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Priorities
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Family history is a variable combination of genetics and shared environment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.2 Genetics Key message
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Risk age can be used in any population regardless of baseline risk and of secular changes in mortality, and therefore avoids the need for re-calibration.68”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Cardiovascular risk age
What the sources say
- Not checked yetcites [68] Cuende, 2010, How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation, Eur Heart J source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Risk will be overestimated in countries with a falling CVD mortality, and underestimated in countries in which mortality is increasing.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > †
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While this is appropriate, many lifestyle measures are less amenable to such assessment than are drug treatments, which will therefore tend to receive a higher grade.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such charts are likely to better represent current risk levels.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Very-high-risk countries
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sedentary subjects and those with central obesity; these characteristics determine many of the other aspects of risk listed below.The increased risk associated with overweight is greater in younger subjects than in older subjects.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > †
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“low-risk countries, suggesting a major problem for women.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Very-high-risk countries
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The risk of CVD in women, as in men, can be reduced by not smoking, by being active, avoiding overweight, and by having a blood pressure and blood cholesterol check (and intervention, if elevated).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.3 Age and gender
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Risk rises with increasing blood sugar concentration before overt diabetes occurs.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > †
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Current systems of grading evidence give most weight to RCTs.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Conclusions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Individuals with low HDL cholesterol, increased triglycerides, fibrinogen, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] levels, especially in combination with familial hypercholesterolaemia, and perhaps increased high-sensitivity CRP (hsCRP).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > †
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The young, women, older people, and ethnic minorities continue to be under-represented in clinical trials.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Conclusions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“CVD is by far the biggest cause of death in women.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.3 Age and gender
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar considerations apply in women who are at lower absolute risk at younger ages and may have high levels of specific risk factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Investment in additional measurements such as imaging with computed tomography to obtain coronary calcium scores may be helpful, 79 but adds considerably to the cost and time involved in risk factor scoring, and its benefit remains unproven.80”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CVD mortality does not accelerate in women following the menopause, indicating that women are postponing their risk rather than avoiding it altogether.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Asymptomatic women and older people benefit from risk scoring to determine management.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Most important new information
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Mechanisms that link psychosocial factors to increased CVD risk include unhealthy lifestyle (more frequent smoking, unhealthy food choice, and less physical exercise), increased healthcare utilization, and low adherence to behaviour-change recommendations or cardiac medications.88,90,116 -119”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.4.2 Clustering of psychosocial risk factors and bio-behavioural mechanisms
What the sources say
- Not checked yetcites [88] Stringhini, 2010, Association of socioeconomic position with health behaviors and mortality, JAMA source
- Not checked yetcites [90] Albert, 2006, Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events, Circulation source
- Not checked yetcites [116] Wamala, 1999, Potential explanations for the educational gradient in coronary heart disease: a population-based case–control study of Swedish women, Am J Public Health source
- Not checked yetcites [117] Chandola, 2008, Work stress and coronary heart disease: what are the mechanisms?, Eur Heart J source
- Not checked yetcites [118] Rozanski, 2005, The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology, J Am Coll Cardiol source
- Not checked yetcites [119] Whooley, 2008, Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease, JAMA source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“At present, MRI is a promising research tool, but its routine use remains limited and it is not yet appropriate for identifying patients at high risk for CVD.146”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.1 Early detection by magnetic resonance imaging of cardiovascular disease in asymptomatic subjects
What the sources say
- Not checked yetcites [146] Greenland, 2000, Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III, Circulation source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“LpPLA2 has recently emerged as a marker with high consistency and precision as an independent risk factor for plaque rupture and atherothrombotic events.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Lipoprotein-associated phospholipase 2
What the sources say
- Not checked yetcites [129] Garza, 2007, Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review, Mayo Clin Proc source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Agatston score is an independent risk marker regarding the extent of CHD 157 and prognostic impact.158”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.2 Coronary calcium score
What the sources say
- Not checked yetcites [157] Hecht, 2001, Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women, J Am Coll Cardiol source
- Not checked yetcites [158] Hadamitzky, 2009, Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease, JACC Cardiovasc Imaging source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The magnitude of effect on risk remains modest at the level of the general population; study limitations or bias are present.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Lipoprotein-associated phospholipase 2
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It is more likely in the setting of unstable angina or non-ST elevation myocardial infarction (NSTEMI) than in stable chest pain, and occurs more frequently in younger patients.155”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.2 Coronary calcium score
What the sources say
- Not checked yetcites [155] Marwan, 2009, Clinical characteristics of patients with obstructive coronary lesions in the absence of coronary calcification: an evaluation by coronary CT angiography, Heart source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No more than mandatory education and/or a 'yes' for one or more items indicates a higher risk than that assessed with the SCORE tools or priority categories.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.4.3 Assessment of psychosocial risk factors
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This variation in disease is probably due to genetic susceptibility, combinations of different risk factors, and interactions between genetic and environmental factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6 Imaging methods in cardiovascular disease prevention
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Atherosclerosis is an inflammatory disease in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.170”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7 Other diseases with increased risk for cardiovascular disease
What the sources say
- Not checked yetcites [170] Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“CVD risk is increased at an early stage of the disease, and this risk excess beyond traditional risk parameters is possibly related to systemic inflammation and a prothrombotic state.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5.2 Rheumatoid arthritis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Patients in whom the psoriasis was classified as severe had a higher risk of myocardial infarction than patients with mild psoriasis, consistent with the hypothesis that greater immune activity in psoriasis is related to a higher risk of myocardial infarction and cardiovascular death.185,186”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5 Autoimmune diseases 3.7.5.1 Psoriasis
What the sources say
- Not checked yetcites [185] Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA source
- Not checked yetcites [186] Mehta, 2010, Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database, Eur Heart J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Periodontitis is associated with endothelial dysfunction, atherosclerosis, and an increased risk of myocardial infarction and stroke.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.6 Periodontitis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plaques are related to both coronary obstructive disease and the risk of cerebrovascular events.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.3 Carotid ultrasound
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Lipid lowering appears useful in a wide range of patients with advanced CKD but with no known history of myocardial infarction or coronary revascularization: a reduction of low-density lipoprotein (LDL) cholesterol by 0.85 mmol/L (33 mg/dL) with daily 20 mg simvastatin plus 10 mg ezetimibe reduced the incidence of major events”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.2 Chronic kidney disease
What the sources say
- Not checked yetcites [174] Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Inflammatory mediators and promoters of calcification are increased and inhibitors of calcification are reduced in CKD, which favours vascular calcification and vascular injury.136”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.2 Chronic kidney disease
What the sources say
- Not checked yetcites [136] Schiffrin, 2007, Chronic kidney disease: effects on the cardiovascular system, Circulation source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, its place in vascular disease risk assessment remains uncertain.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.5 Ophthalmoscopy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Systemic lupus erythematosus is associated with endothelial dysfunction and an increased risk of CHD that is not fully explained by classic CHD risk factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5.3 Lupus erythematosus
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Erectile dysfunction (ED), defined as the consistent inability to reach and maintain an erection satisfactory for sexual activity, afflicts to some degree 52% of male adults between the ages of 40 and 70 years.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.4 Erectile dysfunction
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Coronary microvascular dysfunction is an early marker of accelerated coronary atherosclerosis and may contribute to the increased cardiovascular morbidity and mortality in these patients.189”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5.3 Lupus erythematosus
What the sources say
- Not checked yetcites [189] Recio-Mayoral, 2009, Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease, Eur Heart J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It affects an estimated 9% of adult women and 24% of adult men.175”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.3 Obstructive sleep apnoea
What the sources say
- Not checked yetcites [175] Young, 1993, The occurrence of sleep-disordered breathing among middle-aged adults, N Engl J Med source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The IMT is a measurement not only of early atherosclerosis but also of smooth muscle hypertrophy/hyperplasia, which may be related even to genetic factors, hypertension, and age-related sclerosis.132”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.3 Carotid ultrasound
What the sources say
- Not checked yetcites [132] Sramek, 2000, Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries, Invest Radiol source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The risk of myocardial infarction associated with psoriasis is greatest in young patients with severe psoriasis, is attenuated with age, and remains increased even after controlling for traditional cardiovascular risk factors.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5 Autoimmune diseases 3.7.5.1 Psoriasis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“ED is a marker for CVD and a predictor of future events in middle-aged and older men but not beyond that offered by the Framingham risk score.182 -184”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.4 Erectile dysfunction
What the sources say
- Not checked yetcites [182] Feldman, 2000, Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study, Prev Med source
- Not checked yetcites [183] Jackson, 2006, Erectile dysfunction: a marker of silent coronary artery disease, Eur Heart J source
- Not checked yetcites [184] Araujo, 2010, Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?, J Am Coll Cardiol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“They also have a higher mortality rate after myocardial infarction, which may only partially explain their reduced life expectancy (5-10 years shorter than patients without the condition).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.5.2 Rheumatoid arthritis
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“An ABI value indicating significant PAD adds additional value to medical history, because 50 -89% of patients with an ABI ,0.9 do not have typical claudication.134”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.4 Ankle -brachial index
What the sources say
- Not checked yetcites [134] McDermott, 2002, The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study, Ann Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although there is a graded increase in cardiovascular risk with rising IMT, a value .0.9 mm is considered abnormal.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.3 Carotid ultrasound
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Periodontitis can be considered a risk indicator for a generally decreased cardiovascular health status and its treatment is indicated as well as management of the underlying cardiovascular risk factors.190”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.6 Periodontitis
What the sources say
- Not checked yetcites [190] Tonetti, 2007, Treatment of periodontitis and endothelial function, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“The risk increases to four-to 10-fold in stage 4 (GFR 15 -29 mL/min/1.73m 2 ) and to 10-to 50-fold in stage 5 renal failure (end-stage) (GFR ,15 mL/min/ 1.73 m 2 or dialysis).136”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.2 Chronic kidney disease
What the sources say
- Not checked yetcites [136] Schiffrin, 2007, Chronic kidney disease: effects on the cardiovascular system, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although the relative risk for events is slightly lower after statistical correction for the presence of traditional risk factors, the risk remains elevated at higher IMT.130”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.3 Carotid ultrasound
What the sources say
- Not checked yetcites [130] O'Leary, 1999, Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The extent of carotid IMT is an independent predictor of cerebral and coronary events, but seems to be more predictive in women than in men.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.3 Carotid ultrasound
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“It has been shown that the extent of retinal artery atherosclerosis correlates with the extent of coronary artery atherosclerosis and with serum levels of cholesterol, triglycerides, and apoB.164”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.6.5 Ophthalmoscopy
What the sources say
- Not checked yetcites [164] Tedeschi-Reiner, 2004, Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins, Croat Med J
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Duration also plays a role, and, while cigarette smoking is the most common, all types of smoked tobacco, including low-tar ('mild' or 'light') cigarettes, filter cigarettes, cigars, and pipes, are harmful.211”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.2 Dosage and type
What the sources say
- Not checked yetcites [211] Center for Disease Control and Prevention, 2010, How Tobacco Smoke Causes Disease: The Biology and Behavioural Basis for Smoking-attributable Disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Administration of statins improves endothelial dysfunction, slows the development of cardiac allograft vasculopathy, and benefits survival.194”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 3.7.8 Vascular disease after transplantation
What the sources say
- Not checked yetcites [194] Hunt, 2008, The changing face of heart transplantation, J Am Coll Cardiol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Individuals of low socio-economic status, of older age, or female gender may need tailored programmes in order to meet their specific needs regarding information and emotional support.202,206”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.3 Multimodal, behavioural interventions
What the sources say
- Not checked yetcites [202] Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation source
- Not checked yetcites [206] Burell, 2002, Women's hearts need special treatment, Int J Behav Med source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Smoking is an established cause of a plethora of diseases and is responsible for 50% of all avoidable deaths in smokers, half of these due to CVD.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.1 Introduction
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although the rate of smoking is declining in Europe, it is still very common among individuals who have received little education; and widening education-related inequalities in smoking-cessation rates have been observed in many European countries in recent years.214,216,217”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > I C Strong 211
What the sources say
- Not checked yetcites [214] Edwards, 2004, The problem of tobacco smoking, BMJ source
- Not checked yetcites [216] Huisman, 2005, Inequalities in the prevalence of smoking in the European Union: comparing education and income, Prev Med source
- Not checked yetcites [217] Giskes, 2005, Trends in smoking behaviour between 1985 and 2000 in nine European countries by education, J Epidemiol Community Health source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increased awareness of these factors facilitates empathy and counselling (simple and explicit advice), thus facilitating behavioural change.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.1 Introduction: why do individuals find it hard to change their lifestyle?
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A friendly and positive interaction is a powerful tool to enhance an individual's ability to cope with illness and adhere to recommended lifestyle changes and medication use.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.2 Effective communication and cognitive-behavioural strategies as a means towards lifestyle change
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Reactive oxygen speciesfree radicals-present in inhaled smoke cause oxidation of plasma LDL; oxidized LDL triggers the inflammatory process in the intimae of the arteries through stimulation of monocyte adhesion to the vessel wall, resulting in increased atherosclerosis.232,239 -242”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.4 Mechanism by which tobacco smoking increases risk
What the sources say
- Not checked yetcites [232] Yamaguchi, 2001, Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits, Atherosclerosis source
- Not checked yetcites [239] Weber, 1996, Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers, Circulation source
- Not checked yetcites [240] Weber, 1995, Enhancement of monocyte adhesion to endothelial cells by oxidatively modified low-density lipoprotein is mediated by activation of CD11b, Biochem Biophys Res Commun source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“it is clear that smoking enhances both the development of atherosclerosis and the occurrence of superimposed thrombotic phenomena.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.4 Mechanism by which tobacco smoking increases risk
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition, these factors impede the ability to adopt a healthy lifestyle, as does complex or confusing advice from medical caregivers.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.1 Introduction: why do individuals find it hard to change their lifestyle?
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“In the EUROASPIRE III survey 30% of the participants were smokers up to the time of their coronary event and this had dropped by one-half after a median of 1.5 years.The survey also found that evidence-based treatment for smoking cessation was underused.33”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > I C Strong 211
What the sources say
- Not checked yetcites [33] Kotseva, 2009, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Social support provided by caregivers may be of importance in helping individuals maintain healthy habits and follow medical advice.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.2 Effective communication and cognitive-behavioural strategies as a means towards lifestyle change
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These patterns are framed during childhood and adolescence by an interaction of environmental and genetic factors, and are maintained or even promoted by the individual's social environment as an adult.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.1 Introduction: why do individuals find it hard to change their lifestyle?
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Consequently, marked differences in health behaviour between individuals but also between social groups can be observed.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.1 Introduction: why do individuals find it hard to change their lifestyle?
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“'Lifestyle' is usually based on long-standing behavioural patterns.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.1 Introduction: why do individuals find it hard to change their lifestyle?
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Moving forward in small, consecutive steps is one of the key points in changing long-term behaviour.202”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 7 Principles of effective communication to facilitate behavioural change
What the sources say
- Not checked yetcites [202] Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“goal setting combined with selfmonitoring of the chosen behaviour are the main tools needed to achieve a positive outcome.202”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 7 Principles of effective communication to facilitate behavioural change
What the sources say
- Not checked yetcites [202] Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Previous negative, unsuccessful attempts to change behaviour often result in a lower self-efficacy for future change and often lead to another failure.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 7 Principles of effective communication to facilitate behavioural change
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Individualized counselling is the basis for evoking and gaining the patient's motivation and commitment.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.2 Effective communication and cognitive-behavioural strategies as a means towards lifestyle change
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
In the paper
“The risk associated with smoking is primarily related to the amount of tobacco smoked daily and shows a clear dose-response relationship with no lower limit for deleterious effects.220”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.2 Dosage and type
What the sources say
- Not checked yetcites [220] Prescott, 2002, Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study, J Epidemiol Community Health source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“They enhance coping with illness, and improve adherence with prescribed medication, efforts to change behaviour, and cardiac outcome.195,197,198”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.1.3 Multimodal, behavioural interventions
What the sources say
- Not checked yetcites [195] Dusseldorp, 1999, A meta-analysis of psychoeduational programs for coronary heart disease patients, Health Psychol source
- Not checked yetcites [197] Clark, 2005, Meta-analysis: secondary prevention programs for patients with coronary artery disease, Ann Intern Med source
- Not checked yetcites [198] Auer, 2008, Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Mechanisms have been elucidated through observational cohort studies, experimental observations, and laboratory studies in humans and animals, 225,227 -229 and point towards the effect of smoking on endothelial function, 230,231 oxidative processes, 232 platelet function, 233 fibrinolysis, inflammation, 234 -238 and modification of lipids and vasomotor function.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.4 Mechanism by which tobacco smoking increases risk
What the sources say
- Not checked yetcites [225] Raupach, 2006, Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm, Eur Heart J source
- Not checked yetcites [227] Ambrose, 2004, The pathophysiology of cigarette smoking and cardiovascular disease: an update, J Am Coll Cardiol source
- Not checked yetcites [228] Armani, 2009, Molecular and biochemical changes of the cardiovascular system due to smoking exposure, Curr Pharm Des source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, while the relative risk of myocardial infarction in smokers .60 years of age is doubled, the relative risk in smokers ,50 years is five-fold higher than in non-smokers.214,215”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > I C Strong 211
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Stopping smoking after a myocardial infarction is potentially the most effective of all preventive measures: a systematic review and meta-analysis of 20 cohort studies of smoking cessation after myocardial infarction showed a mortality benefit of 0.64 [95% confidence interval (CI) 0.58-0.71]compared with continued smokers.249”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.5 Smoking cessation
What the sources say
- Not checked yetcites [249] Critchley, 2004, Smoking cessation for the secondary prevention of coronary heart disease, Cochrane Database Syst Rev
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“All available forms of NRT are effective: in a systematic review, the OR for abstinence with NRT vs. control was 1.58 (95% CI 1.50-1.66).213”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.6 Pharmacological aids
What the sources say
- Not checked yetcites [213] Stead, 2008, Nicotine replacement therapy for smoking cessation, Cochrane Database Syst Rev source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both individual and group behavioural interventions are effective in helping smokers quit.225,266 -268”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.7 Other smoking-cessation interventions
What the sources say
- Not checked yetcites [225] Raupach, 2006, Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm, Eur Heart J source
- Not checked yetcites [266] Stead, 2005, Group behaviour therapy programmes for smoking cessation, Cochrane Database Syst Rev source
- Not checked yetcites [267] Lancaster, 2005, Individual behavioural counselling for smoking cessation, Cochrane Database Syst Rev source
- Not checked yetcites [268] Rice, 2004, Nursing interventions for smoking cessation, Cochrane Database Syst Rev source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Public health measures such as smoking bans, tobacco taxation, and media campaigns are efficient aids in preventing smoking uptake and supporting smoking cessation.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.5 Smoking cessation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The risk is rapidly reduced after cessation, with significant morbidity reductions reported within the first 6 months.250”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.5 Smoking cessation
What the sources say
- Not checked yetcites [250] Chow, 2010, Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Cytisine, a low cost partial nicotine receptor agonist available in some European countries, also seems to increase the chances of quitting, but the evidence at present is not conclusive.264”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.6 Pharmacological aids
What the sources say
- Not checked yetcites [264] West, 2011, Placebo-controlled trial of cytisine for smoking cessation, N Engl J Med source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In various studies, low doses of eicosapentaenoic acid and docosahexaenoic acid are associated with a lower risk of fatal CHD but not of non-fatal CHD.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Saturated fatty acids
What the sources say
- Not checked yetcites [271] He, 2004, Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“although there may be several methodological issues explaining this null finding.280”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Saturated fatty acids
What the sources say
- Not checked yetcites [280] Stamler, 2010, Diet–heart: a problematic revisit, Am J Clin Nutr source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“They do not have an impact on serum cholesterol levels, but have been shown to reduce CHD mortality and to a lesser extent stroke mortality.271,282”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Saturated fatty acids
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“the European Medicines Agency has announced that the slightly increased risk of cardiovascular events associated with varenicline does not outweigh the benefits of the drug in helping people to stop smoking.263”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.6 Pharmacological aids
What the sources say
- Not checked yetcites [263] Hawkes, 2011, Varenicline raises risk of heart problems, analysis indicates, BMJ
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The mortality benefit was consistent over gender, duration of follow-up, study site, and time period.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.5 Smoking cessation
What the sources say
- Not checked yetcites [249] Critchley, 2004, Smoking cessation for the secondary prevention of coronary heart disease, Cochrane Database Syst Rev
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The antidepressant nortriptyline and the antihypertensive drug clonidine aid smoking cessation, 258,265 but, owing to side effects, are second-line choices.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.6 Pharmacological aids
What the sources say
- Not checked yetcites [258] Hughes, 2007, Antidepressants for smoking cessation, Cochrane Database Syst Rev source
- Not checked yetcites [265] Gourlay, 2004, Clonidine for smoking cessation, Cochrane Database Syst Rev
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Plaque formation is not thought to be fully reversible and thus smokers would never be expected to reach the risk level of never-smokers concerning CVD.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.2.4 Mechanism by which tobacco smoking increases risk
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The American Institute of Medicine recommends an intake of 3.4 g/MJ, equivalent to an intake of 30 -45 g/day for adults.296”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.2.4 Fibre
What the sources say
- Not checked yetcites [296] Food and Nutrition Board, 2002
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The Seven Countries Study showed a large difference in cardiovascular mortality rates between northern and southern Europe.Even at similar cholesterol levels, and after adjusting for BP and smoking, the difference in cardiovascular risk remained (Figure 8).304”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.5 Dietary patterns
What the sources say
- Not checked yetcites [304] Verschuren, 1995, Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study, JAMA source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The risk of CVD (including CHD and stroke) or CHD alone is significantly reduced in more physically active or fit persons, with a relative risk reduction nearly twice as great for cardiorespiratory fitness than for physical activity increase at all percentiles .25th.308,328,329”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.4.3 Healthy subjects
What the sources say
- Not checked yetcites [308] Schnohr, 2007, Intensity versus duration of walking, impact on mortality: the Copenhagen City Heart Study, Eur J Cardiovasc Prev Rehabil source
- Not checked yetcites [328] Williams, 2001, Physical fitness and activity as separate heart disease risk factors: a meta-analysis, Med Sci Sports Exerc source
- Not checked yetcites [329] Tipton, 2006
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A recent simulation study estimated that for the USA, a reduction in salt intake of 3 g/day would result in a reduction of 5.9 -9.6% in the incidence of CHD (low and high estimate based on different assumptions), a reduction of 5.0 -7.8% in the incidence of stroke, and a reduction of 2.6-4.1% in death from any cause.286”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.2.2 Minerals Sodium
What the sources say
- Not checked yetcites [286] Bibbins-Domingo, 2010, Projected effect of dietary salt reductions on future cardiovascular disease, N Engl J Med source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A modest increase in fish consumption of 1 -2 servings a week would reduce CHD mortality by 36% and all-cause mortality by 17%.298”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Fish
What the sources say
- Not checked yetcites [298] Mozaffarian, 2006, Fish intake, contaminants, and human health: evaluating the risks and the benefits, JAMA source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although the mechanism is not elucidated completely, it is known that a high fibre intake reduces post-prandial glucose responses after carbohydrate-rich meals, and lowers total and LDL cholesterol levels.295”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.2.4 Fibre
What the sources say
- Not checked yetcites [295] Weickert, 2008, Metabolic effects of dietary fiber consumption and prevention of diabetes, J Nutr source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The Cochrane Collaboration concluded in a recent meta-analysis of eight RCTs that homocysteine-lowering interventions did not reduce the risk of fatal/non-fatal myocardial infarction (RR 1.03, 95% CI 0.94-1.13),stroke (RR 0.89, 95% CI 0.73 -1.08), or death by any cause (RR 1.00, 95% CI 0.92-1.09).290”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.2.3 Vitamins
What the sources say
- Not checked yetcites [290] Marti-Carvajal, 2009, Homocysteine lowering interventions for preventing cardiovascular events, Cochrane Database Syst Rev source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“He et al. updated this estimate by adding two additional cohorts, and reported a pooled RR of stroke of 0.89 (95% CI 0.83 -0.97) for those eating 3-5 servings of fruits and vegetables daily compared with those eating ,3 servings, and a pooled RR of 0.74 (95% CI 0.69-0.79)for those eating .5 servings.274”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Fruits and vegetables
What the sources say
- Not checked yetcites [274] He, 2006, Fruit and vegetable consumption and stroke: meta-analysis of cohort studies, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The meta-analysis showed that greater adherence to the Mediterranean diet, by a 2-point higher score, was associated with a 10% reduction in cardiovascular incidence or mortality (pooled RR 0.90, 95% CI 0.87-0.93)and also with an 8% reduction in all-cause mortality (pooled RR 0.92, 95% CI 0.90-0.94).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.3.5 Dietary patterns
What the sources say
- Not checked yetcites [276] Sofi, 2010, Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis, Am J Clin Nutr source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Similarly, regular consumption of sugar-sweetened beverages (i.e. two servings per day compared with one serving per month) was associated with a 35% higher risk of CHD in women, even after other unhealthy lifestyle and dietary factors were accounted for, whereas artificially sweetened beverages were not associated with CHD.301”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Soft drinks
What the sources say
- Not checked yetcites [301] Fung, 2009, Sweetened beverage consumption and risk of coronary heart disease in women, Am J Clin Nutr source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The volume of moderate-intensity physical activity or aerobic exercise training able to provide a reduction in all-cause and cardiovascular mortality ranges from 2.5 to 5 h/week; 306 -308,311,312 the longer the total duration of physical activity/aerobic exercise training performed over the week the greater the observed benefits.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Physical activity intensity and volume
What the sources say
- Not checked yetcites [306] Nocon, 2008, Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis, Eur J Cardiovasc Prev Rehabil source
- Not checked yetcites [307] Lollgen, 2009, Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories, Int J Sports Med source
- Not checked yetcites [308] Schnohr, 2007, Intensity versus duration of walking, impact on mortality: the Copenhagen City Heart Study, Eur J Cardiovasc Prev Rehabil source
- Not checked yetcites [311] US Department of Health and Human Services, 2008, Physical Activity Guidelines Advisory Committee Report
- Not checked yetcites [312] Richardson, 2004, Physical activity and mortality across cardiovascular disease risk groups, Med Sci Sports Exerc source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Insufficient data were available as to the effects of aerobic exercise training on revascularization rates; moreover, aerobic exercise training did not show any effect on the occurrence of non-fatal myocardial infarction.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.4.4 Patients with known cardiovascular disease
What the sources say
- Not checked yetcites [333] Heran, 2011, Exercise-based cardiac rehabilitation for coronary heart disease, Cochrane Database Syst Rev source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In hostile CHD patients, a group-based hostility-control intervention may lead not only to decreases in behaviourally assessed hostility levels, but also to decreased levels of depression, resting heart rate, and cardiovascular reactivity to mental stress, as well as to increased social support and satisfaction with life.359,360”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [359] Gidron, 1999, The short-term effects of a hostility-reduction intervention on male coronary heart disease patients, Health Psychol source
- Not checked yetcites [360] Bishop, 2005, Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting, Am Heart J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moreover, the available evidence suggests that the total weekly volume of physical activity/aerobic exercise training can be obtained by summing multiple daily bouts of exercise, each lasting ≥10 min, and that physical activity/aerobic exercise training should be distributed over most days of the week.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Physical activity intensity and volume
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The occurrence of major cardiovascular events during supervised aerobic exercise training in cardiac rehabilitation programmes is rare: from 1 in 50 000 to 1 in 120 000 patient-hours of exercise, with fatality incidence ranging between 1 in 340 000 and 1 in 750 000 patienthours of exercise.340,341”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Clinical risk assessment
What the sources say
- Not checked yetcites [340] Franklin, 1998, Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16-year follow-up, Chest source
- Not checked yetcites [341] Scheinowitz, 2005, Safety of cardiac rehabilitation in a medically supervised, community-based program, Cardiology source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Overall, moderate to vigorous intensity aerobic exercise training resulted in improved survival in patients with chronic heart failure due to left ventricular systolic dysfunction, and time to readmission to hospital was also significantly extended.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.4.4 Patients with known cardiovascular disease
What the sources say
- Not checked yetcites [310] Piepoli, 2004, Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH), BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A secondary analysis of another RCT found beneficial cardiovascular effects in white men only, 344 and in patients who responded to antidepressant treatment.346”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [344] Schneiderman, 2004, Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial, Psychosom Med source
- Not checked yetcites [346] Carney, 2004, Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study, Psychosom Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Prognosis improvement was higher in patients with ischaemic aetiology, lower left ventricular ejection fraction and peak VO 2 , and higher New York Heart Association class.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.4.4 Patients with known cardiovascular disease
What the sources say
- Not checked yetcites [310] Piepoli, 2004, Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH), BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Coronary patients with clinically significant depression can be safely and effectively treated with psychotherapy 84,85,351 -353 or selective serotonin re-uptake inhibitors, 354 -356 although evidence for a beneficial effect on cardiac endpoints is inconclusive.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [84] Rollman, 2009, Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial, JAMA source
- Not checked yetcites [85] Davidson, 2010, Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial, Arch Intern Med source
- Not checked yetcites [351] Berkman, 2003, Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial, JAMA source
- Not checked yetcites [352] Lesperance, 2007, Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial, JAMA source
- Not checked yetcites [353] Freedland, 2009, Treatment of depression after coronary artery bypass surgery: a randomized controlled trial, Arch Gen Psychiatry source
- Not checked yetcites [354] Glassman, 2002, Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA source
- Not checked yetcites [355] van Melle, 2007, Effects of antidepressant treatment following myocardial infarction, Br J Psychiatry source
- Not checked yetcites [356] Dowlati, 2010, Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis, Can J Psychiatry source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Available risk stratification algorithms help to identify patients who are at increased risk for exercise-related cardiovascular events and who may require more intensive cardiac monitoring, 338,339 and the safety of medically supervised exercise programmes that follow such indications for exercise-related risk stratification is well established.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Clinical risk assessment
What the sources say
- Not checked yetcites [338] American Association of Cardiovascular & Pulmonary Rehabilitation, 2004
- Not checked yetcites [339] American College of Sports Medicine, 2009
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Whereas most studies could show no significant beneficial effect, 84,351 -356 a recent RCT revealed fewer depressive symptoms as well as fewer major adverse cardiac events.85”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [84] Rollman, 2009, Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial, JAMA source
- Not checked yetcites [351] Berkman, 2003, Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial, JAMA source
- Not checked yetcites [352] Lesperance, 2007, Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial, JAMA source
- Not checked yetcites [353] Freedland, 2009, Treatment of depression after coronary artery bypass surgery: a randomized controlled trial, Arch Gen Psychiatry source
- Not checked yetcites [354] Glassman, 2002, Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA source
- Not checked yetcites [355] van Melle, 2007, Effects of antidepressant treatment following myocardial infarction, Br J Psychiatry source
- Not checked yetcites [356] Dowlati, 2010, Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis, Can J Psychiatry source
- Not checked yetcites [85] Davidson, 2010, Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“aerobic exercise training in low-risk patients has been shown to be at least as effective in improving clinical status and myocardial perfusion, and associated with fewer cardiovascular events as compared with an invasive strategy such as a PCI.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.4.4 Patients with known cardiovascular disease
What the sources say
- Not checked yetcites [336] Hambrecht, 2004, Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Stress-management programmes have repeatedly been shown to improve not only subjective well-being but also risk factor levels and CVD outcomes.199,200,358”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [199] Linden, 2007, Psychological treatment of cardiac patients: a meta-analysis, Eur Heart J source
- Not checked yetcites [200] Rees, 2004, Psychological interventions for coronary heart disease, Cochrane Database Syst Rev
- Not checked yetcites [358] Gulliksson, 2011, Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM), Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“One RCT involving a nurse-led, home-based intervention in post-CABG patients revealed beneficial effects on anxiety, but the sample was too small and the follow-up period too short to demonstrate an impact on cardiac events.357”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [357] Lie, 2007, Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial, J Psychosom Res source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Hence, reduction of work stress in managers and supervisors may have beneficial health effects on the target individuals and may also improve perceived social support in their subordinates.362”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
What the sources say
- Not checked yetcites [362] Theorell, 2001, Employee effects of an educational program for managers at an insurance company, Psychosom Med source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In Europe, a recent study of nearly 360 000 participants from nine European countries showed that general obesity and abdominal adiposity are both associated with increased risk of death.372”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.1 Introduction
What the sources say
- Not checked yetcites [372] Pischon, 2008, General and abdominal adiposity and risk of death in Europe, N Engl J Med source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Obesity is becoming a worldwide epidemic in both children and adults.370”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.1 Introduction
What the sources say
- Not checked yetcites [370] Poirier, 2006, Obesity, cardiovascular disease: pathophysiology, evaluation, effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism, Circulation source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“This approach can reduce mood symptoms and enhance health-related quality of life, although evidence for a definite beneficial effect on cardiac endpoints is inconclusive.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Recommendations Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [85] Davidson, 2010, Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial, Arch Intern Med source
- Not checked yetcites [86] Katon, 2010, Collaborative care for patients with depression and chronic illnesses, N Engl J Med source
- Not checked yetcites [199] Linden, 2007, Psychological treatment of cardiac patients: a meta-analysis, Eur Heart J source
- Not checked yetcites [200] Rees, 2004, Psychological interventions for coronary heart disease, Cochrane Database Syst Rev
- Not checked yetcites [343] Whalley, 2011, Psychological interventions for coronary heart disease, Cochrane Database Syst Rev source
- Not checked yetcites [344] Schneiderman, 2004, Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial, Psychosom Med source
- Not checked yetcites [345] Taylor, 2005, Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction, Arch Gen Psychiatry source
- Not checked yetcites [346] Carney, 2004, Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study, Psychosom Med source
- Not checked yetcites [347] Sauer, 2003, Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Evidence is accumulating to suggest that psychological interventions counteract psychosocial stress, promote healthy behaviours, and contribute to the prevention of CVD.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.5.2 Specific interventions to reduce depression, anxiety, and distress
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This process impacts on CVD risk factors and hence on risk, and the mechanical effects of overweight impact on non-cardiovascular causes of morbidity and mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.2 Body weight and risk
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“On the basis of evidence regarding the poorer accuracy and reliability of measuring waist circumference and hip circumference, 381 -383 it is not possible to establish these measures of visceral adiposity as alternatives to BMI in routine practice; it is also notable that BMI was not a stronger predictor of any outcomes than were the other measures, whereas measures of central obesity had somewhat”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 10 Potential adverse cardiovascular effects of increasing body weight
What the sources say
- Not checked yetcites [381] Sebo, 2008, Reliability of doctors' anthropometric measurements to detect obesity, Prev Med source
- Not checked yetcites [382] Nadas, 2008, Intraobserver and interobserver variability of measuring waist circumference, Med Sci Monit
- Not checked yetcites [383] Nordhamn, 2000, Reliability of anthropometric measurements in overweight and lean subjects: consequences for correlations between anthropometric and other variables, Int J Obes Relat Metab Disord source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A recent meta-analysis of 32 studies found no overall difference between BMI, waist circumference, and waist:hip ratio in their association with incident diabetes, 378 and showed no important differences between the sexes.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 10 Potential adverse cardiovascular effects of increasing body weight
What the sources say
- Not checked yetcites [378] Vazquez, 2007, Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis, Epidemiol Rev source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“If, at the population level, obesity is associated with an increased risk of CVD incidence and mortality, among those with established coronary artery disease, the evidence is contradictory.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.4 The obesity paradox in established coronary artery disease
What the sources say
- Not checked yetcites [366] Romero-Corral, 2006, Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies, Lancet source
- Not checked yetcites [367] Oreopoulos, 2008, Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis, Obesity (Silver Spring) source
- Not checked yetcites [368] Hastie, 2010, Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention, Eur Heart J source
- Not checked yetcites [369] Lavie, 2009, Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss, J Am Coll Cardiol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These thresholds have been calculated based on Caucasians and it is apparent that different cut-off points for anthropometric measurements are required in different races and ethnicities.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.3
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In the multicentre European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study, BMI, waist circumference, and waist:hip ratio were all independently associated with allcause mortality; the authors recommended the use of waist circumference or waist:hip ratio in addition to BMI for assessing risk of death; however, no direct comparisons of the magnitudes of associations between”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Table 10 Potential adverse cardiovascular effects of increasing body weight
What the sources say
- Not checked yetcites [372] Pischon, 2008, General and abdominal adiposity and risk of death in Europe, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“ECG LVH can be used as a tool documenting LVH regression, possibly associated with a reduced incidence of new-onset AF. 419”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
- Not checked yetcites [419] Okin, 2004, Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events, JAMA source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Measurement of carotid -femoral pulse wave velocity provides a comprehensive non-invasive assessment of arterial stiffness 423 and has an independent predictive value for all-cause and cardiovascular morbidity, coronary events, and strokes in patients with uncomplicated essential hypertension as well as in the general population.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
- Not checked yetcites [423] Willum-Hansen, 2006, Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Long-acting drugs also minimize BP variability, which may offer protection against progression of organ damage and risk of cardiovascular events.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These alterations are common in untreated hypertensive individuals without target organ damage on routine examination; thus, carotid ultrasound may often detect vascular damage and make risk stratification more precise.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Ultrasound scans limited to common carotid arteries are likely to detect vascular hypertrophy only, whereas assessment of atherosclerosis also requires scanning bifurcations and/or internal carotids where plaques are more frequent.
None of the sources cited for this claim have been checked yet.
In the paper
“A low ABI indicates advanced atherosclerosis, 422 whereas carotid IMT measurements are able to detect earlier changes.421”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Observational evidence is also available that BP levels correlate negatively with cognitive function and that hypertension is associated with an increased incidence of dementia.411”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.1 Introduction
What the sources say
- Not checked yetcites [411] Skoog, 1996, 15-year longitudinal study of blood pressure and dementia, Lancet source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, it is still unclear whether drug-induced diabetes carries the same negative prognosis as naturally occurring diabetes.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.2 Antihypertensive drugs
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In hypertensive patients with and without diabetes, microalbuminuria, even below the currently used threshold values, predicts cardiovascular events, 424 and a continuous relationship between cardiovascular as well as non-cardiovascular mortality and urinary protein/creatinine ratios ≥3.9 mg/g in men and ≥7.5 mg/ g in women has been reported in several studies.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
- Not checked yetcites [424] Sarnak, 2003, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In conclusion, there is evidence that subclinical organ damage predicts cardiovascular death independently of SCORE, and the combination may improve risk prediction, especially in subjects at low or moderate risk (SCORE 1-4%).400”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
- Not checked yetcites [400] Sehestedt, 2010, Risk prediction is improved by adding markers of subclinical organ damage to SCORE, Eur Heart J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A wide pulse pressure (SBP minus DBP) has been shown in some studies to be a better predictor of adverse cardiovascular outcomes than either SBP or DBP individually, 413 and to identify patients with systolic hypertension who are at particularly high risk.414”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.1 Introduction
What the sources say
- Not checked yetcites [413] Franklin, 2001, Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study, Circulation source
- Not checked yetcites [414] Benetos, 2000, A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men, J Am Coll Cardiol source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Elevated BP is a major risk factor for CHD, heart failure, cerebrovascular disease, PAD, renal failure, and atrial fibrillation.”
- Also stated in: § 4.7.1 Introduction · plain
“In a number of epidemiological studies, elevated BP has been identified as a risk factor for CHD, heart failure, cerebrovascular disease, PAD renal failure, and, more recently, atrial fibrillation (AF).409,410”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Key message
What the sources say
- Not checked yetcites [409] MacMahon, 1990, Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias, Lancet source
- Not checked yetcites [410] Wattigney, 2003, Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § 4.7.1 Introduction · plain
In the paper
“Cardiac abnormalities detected by echocardiography more precisely quantify left ventricular mass and geometric LVH patterns, and have an additional predictive power.420”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.7 Risk stratification in hypertension
What the sources say
- Not checked yetcites [420] Taylor, 2007, Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities [ARIC] study), Am J Cardiol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It cannot be ruled out that being underweight is associated with increased cardiovascular morbidity and mortality.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.6.5 Treatment
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reason for the poorer outcome in the intensive group is not clear, but may be associated with hypoglycaemia.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.4 Glucose targets
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fixed-dose combinations simplify treatment and may thus improve patient compliance.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.7.9.3 Combination treatment
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Cardiovascular disease is the leading cause of morbidity and mortality in people with diabetes mellitus.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.8.1 Introduction
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Hypertriglyceridaemia is a significant independent CVD risk factor, but it seems that the association is not as strong as for hypercholesterolaemia.55”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.4 Triglycerides
What the sources say
- Not checked yetcites [55] Sarwar, 2007, Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Familial hypercholesterolaemia is a dominantly inherited condition affecting 1 in 500 people of European descent (heterozygous) most commonly caused by a mutation of the LDL receptor, and is characterized by very high levels of LDL cholesterol (usually 5-10 mmol/L or 200-400 mg/dL).42”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.10 Who should be treated and what are the goals?
What the sources say
- Not checked yetcites [42] Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“There is evidence that non-fasting triglycerides may predict CHD risk even better, as individuals are in the postprandial state most of the time.477”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.4 Triglycerides
What the sources say
- Not checked yetcites [477] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In patients with transient ischaemic attack or ischaemic stroke, a direct comparison of dipyridamole plus aspirin vs. clopidogrel alone 508 showed that the two regimens had similar rates of recurrent stroke, including haemorrhagic stroke (916 vs. 898; HR 1.01, 95% CI 0.92-1.11).There was a higher frequency of major haemorrhagic events with dipyridamole plus aspirin (4.1% vs. 3.6%).Stroke,”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [508] Sacco, 2008, Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke, N Engl J Med source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Remaining gaps in the evidence
What the sources say
- Not checked yetcites [501] Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med source
- Not checked yetcites [502] Gurbel, 2009, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study, Circulation source
- Not checked yetcites [503] Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Statins, by decreasing LDL cholesterol, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions.166,436”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.16 Drugs
What the sources say
- Not checked yetcites [166] Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet source
- Not checked yetcites [436] Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In contrast to earlier observations, recent studies have now shown that high cholesterol levels are a risk factor for ischaemic but not haemorrhagic stroke.489”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.12 Stroke prevention
What the sources say
- Not checked yetcites [489] Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials, JAMA source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In such patients oral vitamin K antagonists are not superior to aspirin but are associated with a higher bleeding risk.512,513”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Class a Level b GRADE Ref C
What the sources say
- Not checked yetcites [512] Mohr, 2001, A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke, N Engl J Med source
- Not checked yetcites [513] Liu, 2000, Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack, Cochrane Database Syst Rev
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Solely reducing dosage demands resulted in strong effects (effect size 0.89-1.20),but other interventions such as repetitive monitoring and feedback (effect size 0.27 -1.2), multisession information (effect size 0.35 -1.13), and combined behavioural interventions (effect size 0.43-1.20)have shown effects ranging from low to strong.520”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Socio-economic
What the sources say
- Not checked yetcites [520] Kripalani, 2007, Interventions to enhance medication adherence in chronic medical conditions: a systematic review, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“As outlined in Table 18, the WHO has categorized potential reasons for medication non-adherence into five broad groupings that include health system-related, condition, patient, therapy, and socio-economic factors.518”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Socio-economic
What the sources say
- Not checked yetcites [518] Ho, 2009, Medication adherence: its importance in cardiovascular outcomes, Circulation source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A recent systematic review has shown that several types of interventions are effective in improving adherence in chronic medical conditions; however, effect sizes on adherence varied and so did medical outcome.520”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Socio-economic
What the sources say
- Not checked yetcites [520] Kripalani, 2007, Interventions to enhance medication adherence in chronic medical conditions: a systematic review, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Remaining gaps in the evidence
What the sources say
- Not checked yetcites [501] Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In a meta-analysis of 16 trials comprising 17 000 individuals, the Antithrombotic Trialists' Collaboration, 2009 507 found that allocation to aspirin was associated with serious vascular events in 6.7% of patients per year vs. 8.2% of controls.The risk of total stroke was 2.08% per year vs. 2.59% (P ¼ 0.002) and coronary events 4.3% per year vs. 5.3% (P ¼ 0.0001).Aspirin was associated with a 10%”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Remaining gaps in the evidence
What the sources say
- Not checked yetcites [507] Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In addition, as adherence with placebo also improves survival, 524 physicians should be aware that adherence to medication may reflect generally better health behaviour.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Socio-economic
What the sources say
- Not checked yetcites [524] Simpson, 2006, A meta-analysis of the association between adherence to drug therapy and mortality, BMJ source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Statin therapy has a beneficial effect on CVD outcomes in CKD stages 2 and 3 and slows the rate of kidney function loss.493”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 4.9.13 Patients with kidney disease
What the sources say
- Not checked yetcites [493] Fellstrom, 2009, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“There is also the issue of undermanagement and little improvement over time in other CVD risk factors such as smoking, high BP, and obesity.540”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.1 Identifying individuals at risk
What the sources say
- Not checked yetcites [540] Wood, 2007, Clinical reality of coronary prevention in Europe: a comparison of EUROPASPIRE I, II, and III surveys. Paper presented at, The 29th Annual Congress of the European Society of Cardiology
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A link exists between accuracy in recordings and both quality of care and adherence to guidelines.437”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.3.3 Improving healthcare using electronic records
What the sources say
- Not checked yetcites [437] Heidenreich, 2011, Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Physicians are also concerned about overestimating risk in national populations, which may lead to overuse of medical therapy.545,547”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.3 Barriers to implementing routine risk assessment
What the sources say
- Not checked yetcites [545] van Steenkiste, 2004, Barriers to implementing cardiovascular risk tables in routine general practice, Scand J Prim Health Care source
- Not checked yetcites [547] Marshall, 2006, Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease, Inform Prim Care
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Affected individuals would include men and elderly individuals who would have a higher tendency to require lipid-lowering medications.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.3 Barriers to implementing routine risk assessment
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Barriers to implementation of risk-adjusted prevention are multiple: risk scoring is considered to be time consuming, simplifying a complex situation, and may result in overmedication.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Most important new information
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other studies have demonstrated the effectiveness of nurse-led prevention clinics in primary care compared with usual care, with greater success in secondary as opposed to primary prevention.532 -534”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Key message
What the sources say
- Not checked yetcites [532] Voogdt-Pruis, 2010, Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial, Br J Gen Pract source
- Not checked yetcites [533] Campbell, 1998, Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care, Heart source
- Not checked yetcites [534] Koelewijn-van Loon, 2010, Improving lifestyle and risk perception through patient involvement in nurse-led cardiovascular risk management: a cluster-randomized controlled trial in primary care, Prev Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although there was no difference in hard endpoints, self-testing gives greater independence and results in a better quality of life.553”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > IIa
What the sources say
- Not checked yetcites [553] Matchar, 2010, Effect of home testing of international normalized ratio on clinical events, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although preferred by many physicians, intuitive assessment based on personal experience appears to underestimate the real risk of CVD: physicians (110 general practitioners and 29 internists) estimated CVD risk as being less severe than detailed in recommendations provided in the WHO-International Society of Hypertension guidelines.542,543”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.2 Use of risk scoring in clinical practice
What the sources say
- Not checked yetcites [542] Persson, 2004, Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy, J Hypertens source
- Not checked yetcites [543] 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee, 1999, J Hypertens
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Nurse case management models tested in several randomized trials of secondary prevention have shown significant improvements in risk factors, exercise tolerance, glucose control, and appropriate medication use, along with decreases in cardiac events and mortality, regression of coronary atherosclerosis, and improved patient perception of health compared with usual care.530,531”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Key message
What the sources say
- Not checked yetcites [530] Berra, 2006, Cardiovascular disease prevention and disease management: a critical role for nursing, J Cardiopulm Rehabil source
- Not checked yetcites [531] Berra, 2011, Global cardiovascular disease prevention: a call to action for nursing: the global burden of cardiovascular disease, J Cardiovasc Nurs source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“More than half of the physicians (57%) believed that the numerical information resulting from prediction rules is frequently unhelpful for clinical decision-making.544”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.3 Barriers to implementing routine risk assessment
What the sources say
- Not checked yetcites [544] Eichler, 2007, Barriers to apply cardiovascular prediction rules in primary care: a postal survey, BMC Fam Pract source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A survey among general practitioners and internists working in clinical practice in two Swiss regions revealed that 74% rarely or never used CVD prediction rules, 544 due to fears of oversimplification of risk assessment (58%) or overuse of medical therapy (54%).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.3 Barriers to implementing routine risk assessment
What the sources say
- Not checked yetcites [544] Eichler, 2007, Barriers to apply cardiovascular prediction rules in primary care: a postal survey, BMC Fam Pract source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the current CVD prevention risk calculators focus on shortterm (5 or 10 year) risk, and therefore inevitably are more likely to classify the elderly as at high risk and the young as at low risk.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.1 Identifying individuals at risk
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A nurse-co-ordinated multidisciplinary prevention programme in both hospitals and primary care practices was evaluated in the EUROACTION trial studying patients with CHD and those at high risk of CVD in eight countries.35 The approach was family centred and led to healthier lifestyle changes in terms of diet and physical activity, improvements in lifestyle (diet and physical activity), and more”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.1.1 Nurse-co-ordinated prevention programmes effective in various healthcare systems
What the sources say
- Not checked yetcites [35] Wood, 2008, Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial, Lancet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Incentives have been shown to be effective in the UK, where the Quality and Outcomes Framework (QOF) scheme links primary care income with achievement of specific evidencebased targets in healthcare delivery.549”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.4 Methods for improving awareness and implementation of risk scoring
What the sources say
- Not checked yetcites [549] Hedback, 1987, 5-year results of a comprehensive rehabilitation programme after myocardial infarction, Eur Heart J source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This will in many patients with perceived low risk often change the risk score profoundly.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.3.1 The cardiologist in general practice: consultant role
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
In the paper
“The evidence shows that nurse case management and nurse-co-ordinated multidisciplinary prevention programmes are more effective than usual care in reducing cardiovascular risk, and can be adapted to a variety of healthcare settings.”
- Also stated in: § 5.1.2 Sustained contact is necessary for lifestyle change · plain
“Nurse-led clinics or nurse-co-ordinated multidisciplinary prevention programmes are more effective than usual care in reducing cardiovascular risk, in a variety of healthcare settings.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.1.2 Sustained contact is necessary for lifestyle change
What the sources say
- Not checked yetcites [531] Berra, 2011, Global cardiovascular disease prevention: a call to action for nursing: the global burden of cardiovascular disease, J Cardiovasc Nurs source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § 5.1.2 Sustained contact is necessary for lifestyle change · plain
In the paper
“An ESC survey conducted in six European countries indicates why physicians rely on their own expertise for the prevention and treatment of CHD: although most cardiologists and physicians (85%) knew they should base CVD risk assessment on the combination of all CVD risk factors, 62% of physicians used subjective methods to gauge risk rather than using risk calculators.541”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.2 Use of risk scoring in clinical practice
What the sources say
- Not checked yetcites [541] Graham, 2006, Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology, Eur J Cardiovasc Prev Rehabil source
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The most common barriers to guideline implementation were government or local health policy (40%), patient compliance (36%), and lack of time (23%).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.2.2 Use of risk scoring in clinical practice
What the sources say
- Not checked yetcites [541] Graham, 2006, Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology, Eur J Cardiovasc Prev Rehabil source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Whether the rehabilitation course is applied in an ambulatory setting or as a residential course is probably of lesser importance; the duration of the programme, the educational level, and the motivation of the patient are also important for long-term outcome.205”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6.4 Repeated sessions improve compliance
What the sources say
- Not checked yetcites [205] Piepoli, 2010, Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation, Eur J Cardiovasc Prev Rehabil source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Multivariable analysis adjusting for 14 clinical variables confirmed that compliance with all performance measures was statistically significantly higher for PCI patients than for CABG patients and was lowest for non-intervention patients.556”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.5 Hospital-based programmes: hospital services 5.5.1 Evidence-based discharge recommendations necessary for optimal therapy
What the sources say
- Not checked yetcites [556] Hiratzka, 2007, Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database, Circulation source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Defect-free (100%) compliance was highest for PCI patients (71.5%), followed by CABG patients (65.1%), then no-intervention patients (62.1%).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.5 Hospital-based programmes: hospital services 5.5.1 Evidence-based discharge recommendations necessary for optimal therapy
What the sources say
- Not checked yetcites [556] Hiratzka, 2007, Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database, Circulation source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The participation rate in a rehabilitation programme after a cardiac event is far lower than desirable: only 30% of eligible patients in Europe participate in such a programme, with considerable variation reported between countries.5”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6.4 Repeated sessions improve compliance
What the sources say
- Not checked yetcites [5] Kotseva, 2009, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Cardiac rehabilitation is considered a cost-effective intervention following an acute coronary event; it improves prognosis by reducing recurrent hospitalizations and healthcare expenditure while prolonging life.562”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6.2 Cardiac rehabilitation is cost-effective
What the sources say
- Not checked yetcites [562] Jolliffe, 2001, Exercise-based rehabilitation for coronary heart disease, Cochrane Database Syst Rev
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Clinical endpoints were also reduced by the intensive intervention: cardiovascular mortality, non-fatal myocardial infarction, and stroke by 33% (P ¼ 0.02), and cardiac death plus non-fatal myocardial infarction by 36% (P ¼ 0.02), total stroke by 32%, and total mortality by 21% (P ¼ not significant).565”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6.2 Cardiac rehabilitation is cost-effective
What the sources say
- Not checked yetcites [565] Giannuzzi, 2008, Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A significant increase was observed in the rate of optimal secondary prevention, with better adherence to guidelines in all patient subgroups, particularly women and the elderly; previously existing treatment gaps were almost eliminated, and improvements were seen in the use of lipid-lowering therapy, ACE inhibitor treatment, and tobaccocessation counselling.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.5.2 Systematic quality improvement programmes are essential
What the sources say
- Not checked yetcites [560] Williams, 2011, Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The intervention proved effective in improving risk factors and increasing medication adherence over time, with significant improvement in lifestyle habits (i.e.exercise, diet, psychosocial stress, and body weight).”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6.2 Cardiac rehabilitation is cost-effective
What the sources say
- Not checked yetcites [565] Giannuzzi, 2008, Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network, Arch Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In randomized studies with a structured treatment regimen and frequent follow-up following an ACS, the compliance rate is high and the event rate low.561”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > 5.6 Hospital-based programmes: specialized prevention centres
What the sources say
- Not checked yetcites [561] Rauch, 2010, OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction, Circulation source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Self-help groups increase independence and improve quality of life.”
§ European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of > Most important new information
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
The paper relies on this without support.
Risk is a continuum and there is no threshold at which a drug is automatically indicated.
“thresholds to trigger certain interventions are problematic since risk is a continuum and there is no threshold at which, for example, a drug is automatically indicated.”
The paper relies on this without support.
Treatment of periodontitis improves endothelial dysfunction, one of the earliest signs of atherosclerosis.
“Treatment of periodontitis improves endothelial dysfunction, one of the earliest signs of atherosclerosis.”
The paper relies on this without support.
Detecting asymptomatic but diseased patients is crucial for an adequate prevention programme.
“Detection of asymptomatic but diseased patients is crucial for an adequate prevention programme.”
The paper relies on this without support.
Management of all risk factors in diseases with increased cardiovascular risk is advisable even without randomized studies.
“Management of all risk factors appears advisable even in the absence of randomized studies.”
The paper relies on this without support.
Motivation is the most important predictor of successful smoking cessation and can be increased by professional assistance.
“The most important predictor of successful quitting is motivation, which can be increased by professional assistance.”
The paper relies on this without support.
The momentum for smoking cessation is particularly strong at the time of diagnosing CVD and in connection with invasive treatment such as CABG, percutaneous transluminal coronary angioplasty, or vascular surgery.
“The momentum for smoking cessation is particularly strong at the time of diagnosing CVD and in connection with an invasive treatment such as CABG, percutaneous transluminal coronary angioplasty, or vascular surgery.”
The paper relies on this without support.
Smoking cessation leads to average weight gain of about 5 kg.
“Smokers should be advised about expected weight gain of on average 5 kg and that the health benefits of tobacco cessation far outweigh the risks from weight gain.”
The paper relies on this without support.
Long-term safety and efficacy data for all pharmacological smoking-cessation therapies are lacking.
“All pharmacological smoking-cessation therapies should be used short term since long-term safety and efficacy data are lacking.”
The paper relies on this without support.
Support from partner and family is very important, and getting other family members who smoke to quit together with the patient is of great help.
“Support from the partner and family is very important.Getting other family members who smoke to quit together with the patient is of great help.”
The paper relies on this without support.
Dietary habits influence cardiovascular risk through effects on risk factors such as serum cholesterol, BP, body weight, and diabetes, or independently of these risk factors.
“Dietary habits are known to influence cardiovascular risk, either through an effect on risk factors such as serum cholesterol, BP, body weight, and diabetes, or through an effect independent of these risk factors.”
The paper relies on this without support.
A healthy diet reduces the risk of other chronic diseases such as cancer.
“A healthy diet also reduces the risk of other chronic diseases such as cancer.”
The paper relies on this without support.
In CVD prevention, the fatty acid composition of the diet is more important than total fat content.
“In prevention, the fatty acid composition of the diet is more important than the total fat content.”
The paper relies on this without support.
Polyunsaturated fatty acids lower LDL cholesterol and, to a lesser extent, HDL cholesterol when they replace saturated fatty acids.
“Polyunsaturated fatty acids lower LDL cholesterol levels, and to a lesser extent HDL cholesterol levels, when they replace saturated fatty acids.”
The paper relies on this without support.
Trans fatty acids increase total cholesterol and decrease HDL cholesterol.
“The subclass of unsaturated fatty acids with a so-called 'trans configuration', the trans fatty acids, have been shown to increase total cholesterol and decrease HDL cholesterol levels.”
The paper relies on this without support.
The impact of dietary cholesterol on serum cholesterol is weak compared with that of fatty acid composition.
“The impact of dietary cholesterol on serum cholesterol levels is weak compared with that of the fatty acid composition of the diet.”
The paper relies on this without support.
The effect of sodium intake on BP is well established.
“The effect of sodium intake on BP is well established.”
The paper relies on this without support.
Higher potassium intake reduces BP.
“A higher potassium intake has been shown to reduce BP.”
The paper relies on this without support.
Case-control and prospective observational studies observed inverse associations between vitamin A and E levels and CVD risk.
“Many case -control and prospective observational studies have observed inverse associations between levels of vitamin A and E and risk of CVDs.”
The paper relies on this without support.
Consumption of dietary fibre reduces the risk of CVD.
“Consumption of dietary fibre reduces the risk of CVD.”
The paper relies on this without support.
Observational studies show a protective effect of fruit and vegetable consumption on CVD prevention.
“Observational studies have shown a protective effect of consumption of fruits and vegetables on CVD prevention.”
The paper relies on this without support.
Results from epidemiological studies show a protective effect of moderate alcohol consumption on CVD occurrence.
“Results from epidemiological studies show a protective effect of moderate alcohol consumption on the occurrence of CVD.”
The paper relies on this without support.
The relationship between alcohol consumption and CVD is J-shaped, not explained by special characteristics of abstainers.
“The relationship is J-shaped, which is not explained by special characteristics of abstainers.”
The authors state this as an assumption.
An intake of 30–45 g/day of fibre is assumed to be the optimal preventive level.
“This intake is assumed to be the optimal preventive level.”
The paper relies on this without support.
After multivariable adjustment, raised blood cholesterol and reduced HDL cholesterol remain independently associated with risk, while the association between weight and risk tends to lose significance.
“Raised blood cholesterol and reduced HDL cholesterol levels remain independently associated with risk after adjustment for other major risk factors, whereas the association between weight and risk tends to lose significance.”
The paper relies on this without support.
Increasing BMI is highly associated with risk of CVD.
“Increasing BMI is highly associated with risk of CVD.”
The paper relies on this without support.
Diet, exercise, and behaviour modifications are mainstay therapies for overweight and obesity but are often unsuccessful for long-term treatment.
“Although diet, exercise, and behaviour modifications are the mainstay therapies for overweight and obesity (Table 12), they are often unsuccessful for long-term treatment.”
The paper relies on this without support.
Major issues in bariatric surgery are lack of consensus on available procedures and need for technique refinement to decrease associated risks.
“The major issues in the field of bariatric surgery are the lack of consensus in terms of the diverse procedures available and of the refinement of techniques that will evolve to decrease the associated risks.”
The paper relies on this without support.
Individuals with elevated BP more commonly have other CVD risk factors (diabetes, insulin resistance, dyslipidaemia) and target organ damage.
“Individuals with an elevated BP more commonly have other risk factors for CVD (diabetes, insulin resistance, dyslipidaemia) and target organ damage.”
The paper relies on this without support.
Ambulatory and home BP monitoring allow diagnosis of white coat or isolated clinic hypertension and masked hypertension.
“They also allow two specific clinical conditions to be diagnosed, namely 'white coat' or isolated clinic hypertension characterized by higher office BP with normal ambulatory BP values, and 'masked' hypertension characterized by normal office BP with high ambulatory BP values.417”
The paper relies on this without support.
BP thresholds for definition of hypertension by 24-h ambulatory and home BP monitoring differ from office or clinic measurements.
“BP thresholds for the definition of hypertension by 24-h ambulatory and home BP monitoring differ from those measured at office or clinic (Table 14).”
The paper relies on this without support.
Diagnosis of hypertension and assessment of treatment are still largely based on office or clinic blood pressure.
“Diagnosis of hypertension and assessment of treatment are still largely based on office or clinic blood pressure.”
The paper relies on this without support.
Established cardiovascular or renal disease dramatically increases risk of subsequent cardiovascular events regardless of BP level.
“Established cardiovascular or renal disease (Table 15) dramatically increases the risk of subsequent cardiovascular events regardless of BP level.”
The paper relies on this without support.
Association of hypertension and other cardiovascular risk factors, especially diabetes, also dramatically increases risk.
“This is also the case for the association of hypertension and other cardiovascular risk factors, not least diabetes.”
The paper relies on this without support.
Echocardiography is more sensitive than electrocardiography in diagnosing LVH and predicting cardiovascular risk, and may help in more precise risk stratification and directing therapy.
“Echocardiography is more sensitive than electrocardiography in diagnosing LVH and in predicting cardiovascular risk, and may help in more precise stratification of the overall risk and in directing therapy.”
The paper relies on this without support.
Ultrasound scans limited to common carotid arteries are likely to detect vascular hypertrophy only, whereas assessment of atherosclerosis also requires scanning bifurcations and/or internal carotids where plaques are more frequent.
“Ultrasound scans limited to the common carotid arteries (an infrequent site of atherosclerosis) are likely to detect vascular hypertrophy only, whereas assessment of atherosclerosis also requires scanning of bifurcations and/or internal carotids where plaques are more frequent.”
The paper relies on this without support.
Evidence of arterial damage may also be suggested by an ABI <0.9.
“Evidence of arterial damage may also be suggested by an ABI ,0.9.”
The paper relies on this without support.
A threshold >12 m/s has been suggested as a conservative estimate of significant alterations of aortic function in middle-aged hypertensive patients.
“Although the relationship between aortic stiffness and events is continuous, a threshold .12m/s has been suggested as a conservative estimate of significant alterations of aortic function in middle-aged hypertensive patients.”
The paper relies on this without support.
Diagnosis of hypertension-induced renal damage is based on reduced renal function and/or elevated urinary albumin excretion.
“The diagnosis of hypertension-induced renal damage is based on the finding of a reduced renal function and/or the detection of elevated urinary albumin excretion.”
The paper relies on this without support.
Renal insufficiency is classified according to eGFR calculated using MDRD, Cockcroft-Gault, or CKD-EPI.
“Renal insufficiency is classified according to the eGFR calculated using the MDRD, Cockroft-Gault formula, or CKD-EPI.”
The paper relies on this without support.
The three formulae help detect mildly impaired renal function, particularly if serum creatinine is within normal range and body weight low and/or age advanced.
“The three formulae help to detect mildly impaired renal function, particularly if serum creatinine values are still within the normal range and the body weight low and/or the age advanced.”
The paper relies on this without support.
Microalbuminuria can be measured from spot urine samples by indexing urinary albumin to creatinine; 24-h or night-time urine samples are discouraged due to inaccuracy.
“Microalbuminuria can be measured from spot urine samples (24-h or night-time urine samples are discouraged due to the inaccuracy of urinary sample collection) by indexing the urinary albumin concentration to the urinary creatinine concentration.”
The paper relies on this without support.
A delay in achieving blood pressure control in high-risk hypertensive patients is associated with a worse outcome.
“A delay in achieving BP control in high-risk hypertensive patients is associated with a worse outcome.”
The paper relies on this without support.
In high-risk hypertensive patients, even intense cardiovascular drug therapy cannot lower total cardiovascular risk below the high-risk threshold.
“This is because, in high-risk hypertensive patients, even intense cardiovascular drug therapy-although beneficialcannot lower total cardiovascular risk below the high-risk threshold.”
The paper relies on this without support.
Tobacco smoking has a particularly adverse effect on cardiovascular risk.
“As tobacco smoking has a particularly adverse effect on cardiovascular risk”
The paper relies on this without support.
Long-term compliance with lifestyle changes may be poor.
“As long-term compliance with lifestyle changes may be poor”
The paper relies on this without support.
In type 2 diabetes, LDL cholesterol often remains within the normal range or is just moderately elevated, while a major CVD risk factor is diabetic dyslipidaemia characterized by hypertriglyceridaemia and low HDL cholesterol.
“However, it has to be stressed that in patients with type 2 diabetes, LDL cholesterol often remains within the normal range or is just moderately elevated, while one of the major CVD risk factors in these patients is diabetic dyslipidaemia characterized by hypertriglyceridaemia and low HDL cholesterol.”
The paper relies on this without support.
There are no randomized trials providing sufficient evidence to derive target levels for triglycerides.
“There are, however, no randomized trials to provide sufficient evidence to derive target levels for triglycerides.”
The paper relies on this without support.
There is insufficient scientific evidence for any HDL cholesterol value to be considered a goal of therapy.
“However, there is still not sufficient scientific evidence for any HDL cholesterol value to be considered as a goal of therapy”
The paper relies on this without support.
The cardiovascular risk associated with hypertriglyceridaemia is stronger for moderate than for very severe hypertriglyceridaemia (>10 mmol/L or 900 mg/dL).
“The risk is associated more strongly with moderate than with very severe hypertriglyceridaemia (.10 mmol/L or 900 mg/dL)”
The paper relies on this without support.
Very severe hypertriglyceridaemia (>10 mmol/L or 900 mg/dL) is a risk factor for pancreatitis.
“which is on the other hand a risk factor for pancreatitis.”
The paper relies on this without support.
Fasting triglycerides above 1.7 mmol/L (150 mg/dL) are a marker of increased cardiovascular risk.
“At present, fasting triglycerides .1.7 mmol/L ( 150 mg/dL) continue to be considered as a marker of increased risk”
The paper relies on this without support.
Measuring non-fasting triglycerides lacks standardization.
“However, due to the lack of standardization, measuring non-fasting triglycerides is not recommended.”
The paper relies on this without support.
The combination of moderately elevated triglycerides and low HDL cholesterol is very common in high-risk patients with type 2 diabetes, abdominal obesity, insulin resistance, and physical inactivity.
“The combination of moderately elevated triglycerides and low concentrations of HDL cholesterol is very common in high-risk patients with type 2 diabetes, abdominal obesity, insulin resistance, and who are physically inactive.”
The paper relies on this without support.
This combination is part of a pattern of deranged plasma lipoproteins characterized by increased triglycerides, small dense LDL particles, and low HDL cholesterol.
“It is part of a pattern of deranged plasma lipoproteins characterized by a triad of increased triglycerides, the presence of small, dense, and very atherogenic LDL particles, and low concentrations of HDL cholesterol.”
The paper relies on this without support.
HDL cholesterol below 1.0 mmol/L in men and below 1.2 mmol/L in women may be regarded as a marker of increased risk.
“although HDL cholesterol ,1.0 mmol/L ( 40 mg/dL) in men and ,1.2 mmol/L ( 45 mg/dL) in women may be regarded as a marker of increased risk.”
The paper relies on this without support.
Measurement of apolipoproteins is not available to all physicians in Europe, is more costly than currently used lipid variables, and does not add more information.
“As the measurement of apolipoproteins is not available to all physicians in Europe, is more costly than currently used lipid variables, and does not add more information”
The paper relies on this without support.
Secondary dyslipidaemias can be caused by alcohol abuse, diabetes, Cushing's syndrome, liver and kidney diseases, and several drugs.
“Secondary dyslipidaemias can also be caused by alcohol abuse, diabetes, Cushing's syndrome, diseases of the liver and kidneys, and several drugs (e.g.corticosteroids, isotretinoin and etretinate, cyclosporin).”
The paper relies on this without support.
Treatment of underlying disease often improves hyperlipidaemia and may make other antilipaemic therapy unnecessary.
“as often the treatment of underlying disease improves hyperlipidaemia and no other antilipaemic therapy is necessary.”
The paper relies on this without support.
Dyslipidaemia is common in organ transplant patients due to underlying disease, lifestyle, and treatments including immunosuppressive therapy.
“Dyslipidaemia is common in patients who have undergone organ transplantation due to a combination of factors relating to the underlying disease, lifestyle, and treatments, including immunosuppressive therapy.”
The paper relies on this without support.
5-10% of patients receiving statins develop myopathy, but rhabdomyolysis is extremely rare.
“5-10% of patients receiving statins develop myopathy, but rhabdomyolysis is extremely rare.”
The paper relies on this without support.
The safety profile of statins is acceptable, and earlier observations that lipid-lowering treatment may increase non-cardiovascular mortality or mental disorders have not been confirmed.
“In general, the safety profile of statins is acceptable, and earlier observations that lipid-lowering treatment may contribute an increase in non-cardiovascular mortality (e.g.cancers, suicides, depression) or mental disorders have not been confirmed.”
The paper relies on this without support.
Bile acid sequestrants decrease total and LDL cholesterol but tend to increase triglyceride concentrations.
“Bile acid sequestrants also decrease total and LDL cholesterol but tend to increase triglyceride concentrations.”
The paper relies on this without support.
Combinations of a statin and a bile acid sequestrant or a statin and ezetimibe can achieve greater LDL cholesterol reduction than either drug alone.
“Combinations of a statin and a bile acid sequestrant or a combination of a statin and ezetimibe can be used for greater reduction of LDL cholesterol than can be achieved with either drug alone.”
The paper relies on this without support.
Combinations of niacin and a statin increase HDL cholesterol and decrease triglycerides better than either drug alone, but flushing is the main adverse effect of niacin, which may affect compliance.
“Combinations of niacin and a statin increase HDL cholesterol and decrease triglycerides better than either of these drugs alone, but flushing is the main adverse effect of niacin, which may affect compliance.”
The paper relies on this without support.
Adding laropiprant to niacin might help reduce the incidence of flushing.
“Adding laropiprant to niacin might help in reducing the incidence of this adverse effect.”
The paper relies on this without support.
Fibrates, particularly fenofibrate, may be useful for decreasing high triglycerides and increasing low HDL cholesterol, and can further lower LDL cholesterol when combined with a statin.
“Fibrates, particularly fenofibrate, may be useful, not only for decreasing high triglyceride concentrations and increasing low HDL cholesterol, but can further lower LDL cholesterol when applied together with a statin.”
The paper relies on this without support.
Stroke is the most serious complication of atrial fibrillation.
“Stroke is the most serious complication of AF.”
The paper relies on this without support.
Atrial fibrillation is often unrecognized and untreated in patients admitted with acute ischaemic stroke.
“AF is often unrecognized and untreated in patients admitted with acute ischaemic stroke.”
The paper relies on this without support.
Cost-related medication non-adherence is a relevant problem in many healthcare systems, especially in the elderly and people of low socio-economic status.
“Cost-related medication non-adherence is a relevant problem in many healthcare systems, especially in the elderly and people of low socio-economic status.”
The paper relies on this without support.
Cardiovascular disease is the single most important cause of death for both men and women and can often be prevented.
“Cardiovascular disease is the single most important cause of death for both men and women and can often be prevented!”
The paper relies on this without support.
After a cardiovascular event, secondary preventive efforts within a structured rehabilitation programme have been shown to be particularly important and cost-effective.
“After a cardiovascular event, secondary preventive efforts within a structured rehabilitation programme have been shown to be particularly important and cost-effective.”
The paper relies on this without support.
Smoking bans in public places, by law, lead to a decrease in incidence of myocardial infarction.
“Smoking bans in public places, by law, lead to a decrease in incidence of myocardial infarction.”
The paper relies on this without support.
Microalbuminuria is a risk factor for cardiovascular disease, rising progressively from normal GFR to end-stage renal disease.
“Microalbuminuria is a risk factor for CVD, which rises progressively from a normal GFR to end-stage renal disease.”
The paper relies on this without support.
Effective prevention programmes are undeniably needed.
“However, the need for effective prevention programmes is undeniable, and the evidence shows that nurses can successfully lead or co-ordinate such schemes in a variety of settings.”
The paper relies on this without support.
General practitioners are critical to the implementation and success of CVD prevention programmes in Europe.
“General practitioners are critical to the implementation and success of CVD prevention programmes in Europe.”
The paper relies on this without support.
In most countries, general practitioners deliver more than 90% of consultations and provide most public health medicine.
“In most countries, they deliver .90% of consultations and provide most public health medicine (preventive care, disease screening, chronic disease monitoring, and follow-up).”
The paper relies on this without support.
Primary prevention of CVD performs worse at least partly because it is more difficult to predict who is at greater risk and may benefit from treatment.
“The performance of primary prevention of CVD is even worse, at least partly because of additional difficulties in predicting those at greater risk who may benefit from treatment interventions.”
The paper relies on this without support.
Most cases of CVD are preventable through lifestyle changes and appropriate use of medications already in existence.
“It was concluded that most cases of CVD are preventable through lifestyle changes and appropriate use of medications already in existence.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [174]
The cited source says what the claim attributes to it.
In the citing paper
“For people with documented ASCVD, use of aspirin for secondary prevention has far greater benefit than risk; for this indication, aspirin is still recommended (174).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [174]
In the citing paper
“The European Guidelines on CVD prevention in clinical practice (both the 2012 [9] and 2016 [10] versions) recommend the use of the SCORE system because it is based on large, representative European cohort data sets and because it is relatively straightforward to recalibrate for individual countries.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [9]
In the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [140]
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk patients with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [140]
In the citing paper
“The European Guidelines on CVD prevention in clinical practice (version 2012) 6 recommend use of the SCORE system because it is based on large, representative European cohort datasets.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [6]
In the citing paper
“However, the JPAD studies conducted in Japan did not show any protective effects of aspirin on cardiovascular events in patients with DM825, 826).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [826]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Conflicting blood-pressure threshold for starting treatment in diabetes
MajorOne section says to initiate antihypertensive treatment in diabetes at ≥140/90 mmHg; the diabetes section says ≥140/80 mmHg. These thresholds give different treatment decisions for a patient whose systolic pressure is at least 140 and diastolic pressure is between 80 and 89 mmHg.
“In patients with diabetes, antihypertensive treatment should always be initiated when the BP is ≥140/90 mmHg.”
“In diabetic patients, antihypertensive treatment should be initiated when the BP is ≥140/80 mmHg.”
Citations
Cites
3 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
RetractedShaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedSmoking cessation for the secondary prevention of coronary heart disease
Critchley, J., & Capewell, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003041.pub2 · Cited by 342
RetractedFriedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Flagged first, then by citations
Research works printed but not linked: 24
- SIGN (Scottish Intercollegiate Guidelines Network), 2007, Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline
- World Health Organization, 2002, Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases
- World Health Organization, Regional Office for Europe, 1973, The Prevention and Control of Major Cardiovascular Diseases. Report of a Conference
- Tunstall-Pedoe H (World Health Organization), 2003, MONICA Monograph and Multimedia Sourcebook
- Vander Stichele, 2008, Is the decline in coronary attack rates leveling off in Flanders?, Eur J Cardiovasc Prev Rehabil, 15 suppl 1, S1
- National Institute for Health and Clinical Excellence, 2010, Prevention of Cardiovascular Disease: Costing Report
- Cooney, 2009, How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators, Eur J Cardiovasc Prev Rehabil, 16, 304, 10.1097/hjr.0b013e3283213140 · DOI · Paper page
- Cooney, 2009, HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk, Atherosclerosis, 206, 611, 10.1016/j.atherosclerosis.2009.02.041 · DOI · Paper page
- World Health Organization, Global Health Observatory Data Repository
- Fajardo, 1999, Is the pathology of radiation injury different in small vs large blood vessels?, Cardiovasc Radiat Med, 1, 108
- Thun, 1997, Age and the exposure–response relationships between cigarette smoking and premature death in Cancer Prevention Study II, 383
- Center for Disease Control and Prevention, 2010, How Tobacco Smoke Causes Disease: The Biology and Behavioural Basis for Smoking-attributable Disease
- WHO Study Group on Tobacco Product Regulation TobReg, 2005, Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators
- International Agency for Research on Cancer, 2007, Tobacco Control: Reversal of Risk After Quitting Smoking. IARC Handbooks of Cancer Prevention
- National Institute for Health and Clinical Excellence, 2008, NICE Public Health Guidance 10. Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities
- European Heart, 2011, Diet, Physical Activity and Cardiovascular Disease Prevention in Europe
- Abuannadi, 2011, Give me sunshine: vitamin D cardiovascular health, Prim Care Cardiovasc J, 4, 59
- US Department of Health and Human Services, 2008, Physical Activity Guidelines Advisory Committee Report
- US Department of Health and Human Services, 2008, 2008 Physical Activity Guidelines for Americans
- World Health Organization, 1998, Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation, World Health Organization Technical Report Series
- Lohman, 1998, Anthoropometric Standardization Reference Manual
- Antithrombotic Trialists' Collaboration, 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
- Liu, 2000, Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack, Cochrane Database Syst Rev, 2
- Wood, 2007, Clinical reality of coronary prevention in Europe: a comparison of EUROPASPIRE I, II, and III surveys. Paper presented at, The 29th Annual Congress of the European Society of Cardiology
Cited by
Sorted by citations
Items 801–900 of 1,089
Xu, S., Xu, Y., Liu, P., Zhang, S., Liu, H., Slavin, S. A., Kumar, S., Koroleva, M., Luo, J., Wu, X., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz303 · Cited by 105
Functional food and nutra‐pharmaceutical perspectives of date ( Phoenix dactylifera L.) fruit
Younas, A., Naqvi, S. A., Khan, M. R., Shabbir, M. A., Jatoi, M. A., Anwar, F., Inam‐Ur‐Raheem, M., Saari, N., & Aadil, R. M. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13332 · Cited by 115
Ciccone, M. M., Cortese, F., Pinto, M., Teo, C. D., Fornarelli, F., Gesualdo, M., Mezzina, A., Sabatelli, E., Scicchitano, P., & Quaranta, N. A. A. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.024 · Cited by 105
Burén, J., Ericsson, M., Damasceno, N., & Sjödin, A. (2021) · Nutrients · doi:10.3390/nu13030814 · Cited by 104
Xu, L., Borges, M. C., Hemani, G., & Lawlor, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4396-y · Cited by 104
Degano, I. R., Elosúa, R., & Marrugat, J. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.01.018 · Cited by 104
Coronary Artery Calcium and Long-Term Risk of Death, Myocardial Infarction, and Stroke
Mitchell, J. D., Paisley, R., Moon, P., Novak, E., & Villines, T. C. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.09.003 · Cited by 107
de Gonzalo‐Calvo, D., Vea, À., Bär, C., Fiedler, J., Couch, L. S., Brotons, C., Llorente‐Cortés, V., & Thum, T. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy234 · Cited by 105
Self-citationDalbosco-Salas, M., Torres‐Castro, R., Leyton, A. R., Zapata, F. M., Salazar, E. H., Bastías, G. E., Díaz, M. E. B., Allers, K. T., Fonseca, D. M., & Vilaró, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194428 · Cited by 109
Impact of time since last caloric intake on blood glucose levels
Moebus, S., Göres, L., Lösch, C., & Jöckel, K. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9608-z · Cited by 107
Guimarães, G. V., Cruz, L. G. D. B., Fernandes-Silva, M. M., Dórea, E. L., & Bocchi, E. A. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.01.100 · Cited by 106
Statins for primary prevention of cardiovascular disease
Majeed, A. (2014) · BMJ · doi:10.1136/bmj.g3491 · Cited by 103
Hsu, D. C., & Sereti, I. (2016) · Drugs · doi:10.1007/s40265-016-0546-7 · Cited by 102
Impact of mHealth technology on adherence to healthy PA after stroke: a randomized study
Pellicer, M. G., Lalanza, J. F., Jovell, E., & Capdevila, L. (2019) · Topics in Stroke Rehabilitation · doi:10.1080/10749357.2019.1691816 · Cited by 111
Frailty and cardiovascular mortality in more than 3 million US Veterans
Shrauner, W. R., Lord, E. M., Nguyen, X. T., Song, R. J., Galloway, A., GAGNON, D. R., Driver, J. A., Gaziano, J. M., Wilson, P. W. F., Djoussé, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab850 · Cited by 108
Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient
Budoff, M. J., Raggi, P., Beller, G., Berman, D. S., Druz, R. S., Malik, S., Rigolin, V. H., Weigold, W. G., & Soman, P. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2015.11.011 · Cited by 104
Clinical relevance of high sensitivity C-reactive protein in cardiology
Adukauskienė, D., Čiginskienė, A., Adukauskaitė, A., Pentiokinienė, D., Šlapikas, R., & Čeponienė, I. (2016) · Medicina · doi:10.1016/j.medici.2015.12.001 · Cited by 102
Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment
Hinojar, R., Foote, L., Sangle, S. R., Marber, M. S., Mayr, M., Carr‐White, G., D’Cruz, D. P., Nagel, E. C., & Püntmann, V. O. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.182 · Cited by 101
Gelbenegger, G., Postula, M. A., Pecen, L., Halvorsen, S., Lesiak, M., Schoergenhofer, C., Jilma, B., Hengstenberg, C., & Siller-Matula, J. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1428-0 · Cited by 107
Banach, M., Penson, P. E., Vrablı́k, M., Bunc, M., Dyrbuś, K., Fedačko, J., Gaiță, D. I., Gierlotka, M. J., Járai, Z., Magda, S. L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105499 · Cited by 102
Self-citationAntiplatelet Therapy: Targeting the TxA2 Pathway
Fontana, P., Zufferey, A., Daali, Y., & Reny, J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9529-1 · Cited by 102
Fernández‐Ortíz, A., Jiménez‐Borreguero, L. J., Peñalvo, J. L., Ordovás, J. M., Mocoroa, A., Fernández‐Friera, L., Laclaustra, M., García, L., Molina, J., Mendiguren, J. M., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.08.024 · Cited by 102
Kleber, M. E., Delgado, G. E., Lorkowski, S., März, W., & von Schacky, C. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.049 · Cited by 100
Commentary: Mendelian randomization-inspired causal inference in the absence of genetic data
Zuccolo, L., & Holmes, M. V. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw327 · Cited by 102
Pirro, M., Vetrani, C., Bianchi, C., Mannarino, M. R., Bernini, F., & Rivellese, A. A. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.122 · Cited by 99
Borghi, C., Tubach, F., De Backer, G., Dallongeville, J., Guallar, E., Medina, J., Perk, J., Roy, C., Banegas, J. R., Rodriguez-Artalejo, F., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.044 · Cited by 102
Self-citationDanger Signaling in Atherosclerosis
Zimmer, S., Grebe, A., & Latz, E. (2015) · Circulation Research · doi:10.1161/circresaha.116.301135 · Cited by 106
Viguiliouk, E., Blanco Mejia, S., Kendall, C. W. C., & Sievenpiper, J. L. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13312 · Cited by 101
Timpka, S., Stuart, J. J., Tanz, L. J., Rimm, E. B., Franks, P. W., & Rich-Edwards, J. W. (2017) · BMJ · doi:10.1136/bmj.j3024 · Cited by 105
Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood
Bavineni, M., Wassenaar, T. M., Agnihotri, K., Ussery, D. W., Lüscher, T. F., & Mehta, J. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz025 · Cited by 109
Candelaria, D., Randall, S., Ladak, L. A., & Gallagher, R. D. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02338-y · Cited by 108
Primary prevention of stroke: blood pressure, lipids, and heart failure
Endres, M., Heuschmann, P. U., Laufs, U., & Hakim, A. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq472 · Cited by 107
The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment
Economou, E. K., Oikonomou, E. K., Siasos, G., Παπαγεωργίου, Ν., Tsalamandris, S., Mourouzis, K., Papaioannou, S., & Tousoulis, D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.037 · Cited by 102
Prediction of Asymptomatic Carotid Artery Stenosis in the General Population
de Weerd, M., Greving, J. P., Hedblad, B., Lorenz, M., Mathiesen, E. B., O’Leary, D. H., Rosvall, M., Sitzer, M., de Borst, G. J., Buskens, E., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.005145 · Cited by 100
Weng, S. F., Kai, J., Neil, H. A. W., Humphries, S. E., & Qureshi, N. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.034 · Cited by 104
White Rice Consumption and CVD Risk Factors among Iranian Population
Khosravi‐Boroujeni, H., Sarrafzadegan, N., Mohammadifard, N., Sajjadi, F., Maghroun, M., Sedigheh, A., Rafieian‐Kopaei, M., & Azadbakht, L. (2013) · Journal of Health Population and Nutrition · doi:10.3329/jhpn.v31i2.16390 · Cited by 100
Gierlotka, M. J., Zdrojewski, T. R., Wojtyniak, B., Poloński, L., Stokwiszewski, J., Gąsior, M., Kozierkiewicz, A., Kalarus, Z. F., Wierucki, Ł., Chlebus, K., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0213 · Cited by 100
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Baumert, M., Immanuel, S. A., Stone, K. L., Harrison, S. L., Redline, S. S., Mariani, S., Sanders, P., McEvoy, R. D., & Linz, D. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy838 · Cited by 102
Nacul, L., O’Boyle, S., Palla, L., Nácul, F. E., Mudie, K., Kingdon, C. C., Cliff, J. M., Clark, T. G., Dockrell, H. M., & Lacerda, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00826 · Cited by 104
Long-term effectiveness, outcomes and complications of bariatric surgery
Gulinac, M., Miteva, D., Peshevska-Sekulovska, M., Novakov, I. P., Antović, S., Peruhova, M., Snegarova, V., Kabakchieva, P., Assyov, Y. S., Vasilev, G., et al. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i19.4504 · Cited by 115
Priyanto, A. D., Doerksen, R. J., Chang, C., Sung, W., Widjanarko, S. B., Kusnadi, J., Lin, Y., Wang, T.-C., & Hsu, J. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.08.018 · Cited by 100
Sutcliffe, P. A., Connock, M. J., Gurung, T., Freeman, K., Johnson, S. A., Kandala, N., Grove, A., Gurung, B., Morrow, S., & Clarke, A. (2013) · Health Technology Assessment · doi:10.3310/hta17430 · Cited by 99
Dual agonist occupancy of AT1-R–α2C-AR heterodimers results in atypical Gs-PKA signaling
Bellot, M., Galandrin, S., Boularan, C., Matthies, H. J. G., Despas, F., Denis, C., Javitch, J. A., Mazères, S., Sanni, S. J., Pons, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1766 · Cited by 99
Hulsegge, G., Looman, M., Smit, H. A., Daviglus, M. L., van der Schouw, Y. T., & Verschuren, W. M. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002432 · Cited by 102
Predicting coronary artery disease: a comparison between two data mining algorithms
Ayatollahi, H., Gholamhosseini, L., & Salehi, M. (2019) · BMC Public Health · doi:10.1186/s12889-019-6721-5 · Cited by 98
Canova, C., Barbieri, G., Jeddi, M. Z., Gion, M., Fabricio, A. S. C., Daprà, F., Russo, F., Fletcher, T., & Pitter, G. (2020) · Environment International · doi:10.1016/j.envint.2020.106117 · Cited by 101
Dempsey, P. C., Friedenreich, C. M., Leitzmann, M. F., Buman, M. P., Lambert, E. V., Willumsen, J. F., & Bull, F. (2020) · Journal of Physical Activity and Health · doi:10.1123/jpah.2020-0525 · Cited by 109
Matsumoto, C., Miedema, M. D., Ofman, P., Gaziano, J. M., & Sesso, H. D. (2014) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000042 · Cited by 105
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Blood pressure control and knowledge of target blood pressure in coronary patients across Europe
Prugger, C., Keil, U., Wellmann, J., Bacquer, D. D., Backer, G. D., Ambrosio, G. B., Reiner, Ž., Gaiță, D. I., Wood, D., Kotseva, K., et al. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328348efa7 · Cited by 99
Self-citationSattar, N. A., Ginsberg, H. N., Ray, K. K., Chapman, M. J., Arca, M., Averna, M. R., Betteridge, D. J., Bhatnagar, D., Bilianou, E., Carmena, R., et al. (2014) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2014.04.001 · Cited by 99
Rosengren, A., Åberg, M., Robertson, J., Wærn, M., Schaufelberger, M., Kuhn, H. G., Åberg, N. D., Schiöler, L., & Torén, K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw221 · Cited by 100
Timpka, S., Fraser, A., Schyman, T., Stuart, J. J., Åsvold, B. O., Mogren, I., Franks, P. W., & Rich-Edwards, J. W. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0429-1 · Cited by 99
Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults
Rahimi, K., Mohseni, H., Kiran, A., Tran, J., Nazarzadeh, M., Rahimian, F., Woodward, M., Dwyer, T., MacMahon, S. W., & Otto, C. M. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy486 · Cited by 104
Berkelmans, G. F. N., Guðbjörnsdóttir, S., Visseren, F. L. J., Wild, S. H., Franzén, S., Chalmers, J. P., Davis, B. R., Poulter, N. R., Spijkerman, A. M. W., Woodward, M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy839 · Cited by 98
Accelerometer-derived physical activity and risk of atrial fibrillation
Khurshid, S. S., Weng, L.-C. C., Al‐Alusi, M. A., Halford, J. L., Haimovich, J. S., Benjamin, E. J., Trinquart, L., Ellinor, P. T., McManus, D. D., & Lubitz, S. A. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab250 · Cited by 98
Virtual and in-person cardiac rehabilitation
Dalal, H. M., Doherty, P., McDonagh, S. T. J., Paúl, K., & Taylor, R. S. (2021) · BMJ · doi:10.1136/bmj.n1270 · Cited by 93
Barrios, V., Escobar, C., Cicero, A. F. G., Burke, D., Fasching, P., Banach, M., & Bruckert, E. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.003 · Cited by 96
Exercise Therapy in Hypertensive Cardiovascular Disease
Fagard, R. H. (2011) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.03.006 · Cited by 98
Self-citationCurrent therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review
Raheem, O. A., Su, J. J., Wilson, J. R., & Hsieh, T. (2016) · American Journal of Men s Health · doi:10.1177/1557988316630305 · Cited by 101
Haybar, H., Javid, A. Z., Haghighizadeh, M. H., Valizadeh, E., Mohaghegh, S. M., & Mohammadzadeh, A. (2018) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2018.04.015 · Cited by 97
van der Aalst, C. M., Denissen, S. J. A. M., Vonder, M., Gratama, J. W., Adriaansen, H. J., Kuijpers, D., Vliegenthart, R., van Lennep, J. E. R., van der Harst, P., Braam, R. L., et al. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa168 · Cited by 97
Anselmi, F., Cavigli, L., Pagliaro, A., Valente, S., Valentini, F., Cameli, M., Focardi, M., Mochi, N., Dendale, P., Hansen, D., et al. (2021) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.14007 · Cited by 96
Kruppa, J., Liu, Y., Biau, G., Kohler, M., König, I. R., Malley, J. D., & Ziegler, A. (2014) · Biometrical Journal · doi:10.1002/bimj.201300068 · Cited by 97
Sliwa, K. S., Stewart, S., & Gersh, B. J. (2011) · Circulation · doi:10.1161/circulationaha.110.992362 · Cited by 97
Pre‐eclampsia: an important risk factor for asymptomatic heart failure
Ghossein‐Doha, C., van Neer, J., Wissink, B., Breetveld, N. M., Windt, L. J. D., van Dijk, A. P. J., van der Vlugt, M. J., Janssen, M. C. H., Heidema, W. M., Scholten, R. R., et al. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17343 · Cited by 98
Cardiac Tissues From Stem Cells: New Routes to Maturation and Cardiac Regeneration
Campostrini, G., Windt, L. M., van Meer, B. J., Bellin, M., & Mummery, C. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318183 · Cited by 96
Omega-3 fatty Acids in cardiovascular disease – An uphill battle
von Schacky, C. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.05.004 · Cited by 100
Ferrari, R., Aguíar, C., Alegría, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
Self-citationExergaming and Virtual Reality for Health: Implications for Cardiac Rehabilitation
Bond, S., Laddu, D., Ozemek, C., Lavie, C. J., & Arena, R. A. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.100472 · Cited by 96
Çetın, M., Çakıcı, M., Zencır, C., Taşolar, H., Baysal, E., Ballı, M., & Aktürk, E. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.056 · Cited by 96
Eussen, S. R. B. M., Geleijnse, J. M., Giltay, E. J., Rompelberg, C. J. M., Klungel, O. H., & Kromhout, D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr499 · Cited by 97
Pérez-Piñar, M., Mathur, R., Boreu, Q. F., Ayis, S. A., Robson, J. P., & Ayerbe, L. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.02.004 · Cited by 103
Leiter, L. A., Lundman, P., da Silva, P. M., Drexel, H., Jünger, C., Gitt, A. K., & on behalf of the DYSIS investigators (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03360.x · Cited by 95
Poręba, R., Gać, P., Poręba, M., & Andrzejak, R. (2010) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2010.12.002 · Cited by 97
Lower Mortality Rate in Elderly Patients With Community‐Onset Pneumonia on Treatment With Aspirin
Falcone, M., Russo, A., Cangemi, R., Farcomeni, A., Calvieri, C., Barillà, F., Scarpellini, M. G., Bertazzoni, G., Palange, P., Taliani, G., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001595 · Cited by 98
Putting polypills into practice: challenges and lessons learned
Webster, R. J., Castellano, J. M., & Onuma, O. K. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30558-5 · Cited by 93
Ávila, A., Claes, J., Goetschalckx, K., Buys, R., Azzawi, M., Vanhees, L., & Cornelissen, V. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9943 · Cited by 96
Bäck, M., Caldenius, V., Svensson, L. A., & Lundberg, M. (2020) · Physical Therapy · doi:10.1093/ptj/pzaa159 · Cited by 106
Nagatomi, Y., Ide, T., Higuchi, T., Nezu, T., Fujino, T., Tohyama, T., Nagata, T., Higo, T., Hashimoto, T., Matsushima, S., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13934 · Cited by 95
Yoga for the primary prevention of cardiovascular disease
Hartley, L., Dyakova, M., Holmes, J., Clarke, A., Lee, M. S., Ernst, E., & Rees, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010072.pub2 · Cited by 95
Duclos, M., Oppert, J., Vergès, B. L., Coliche, V., Gautier, J., Guezennec, Y., Reach, G., & Strauch, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.005 · Cited by 92
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
Mertens, E., Markey, O., Geleijnse, J. M., Lovegrove, J. A., & Givens, D. I. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1408-0 · Cited by 97
Sarkar, C., Webster, C. J., & Gallacher, J. (2018) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2018.01.009 · Cited by 104
Brassington, K., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Clinical Science · doi:10.1042/cs20180316 · Cited by 97
Periodontitis and Hypertension: Is the Association Causal?
Pinto, R. D., Pietropaoli, D., Aguilera, E. M., D’Aiuto, F., Cześnikiewicz‐Guzik, M., Monaco, A., Guzik, T. J., & Ferri, C. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00392-z · Cited by 103
Petermann-Rocha, F. E., Parra-Soto, S. L., Gray, S. R., Anderson, J. J., Welsh, P. I., Gill, J. M. R., Sattar, N. A., Ho, F. K. W., Celis-Morales, C. A., & Pell, J. P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa939 · Cited by 95
Pasqualini, D., Bergandi, L., Palumbo, L., Borraccino, A., Dambra, V., Alovisi, M., Migliaretti, G., Ferraro, G., Ghigo, D., Bergerone, S., et al. (2012) · Journal of Endodontics · doi:10.1016/j.joen.2012.08.013 · Cited by 96
Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox
González-Gay, M. Á., & González‐Juanatey, C. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204933 · Cited by 94
Verbreitung von Fettstoffwechselstörungen bei Erwachsenen in Deutschland
Scheidt‐Nave, C., Du, Y., Knopf, H., Schienkiewitz, A., Ziese, T., Nowossadeck, E., Gößwald, A., & Busch, M. A. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1670-0 · Cited by 95
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
Saiz, L. C., Gorricho, J., Garjón, J., Celaya, M. C., Muruzábal, L., Malón, M. D. M., Montoya, R., & López, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010315.pub2 · Cited by 93
Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease
Mirtschink, P., Jang, C., Arany, Z. P., & Krek, W. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx518 · Cited by 95
Coronary arterial calcification: A review of mechanisms, promoters and imaging
Andrews, J., Psaltis, P. J., Bartolo, B. A. D., Nicholls, S. J., & Puri, R. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.04.007 · Cited by 95
Clark, D., Nicholls, S. J., John, J. S., Elshazly, M. B., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Puri, R. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy209 · Cited by 93
Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases
Escarcega, R. O., Lipinski, M. J., García‐Carrasco, M., Pinto, C. M., Gálvez-Romero, J. L., & Cervera, R. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.021 · Cited by 93
Lee, S., Sung, J. M., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K. M., Choi, J. H., Chun, E. J., Conte, E., et al. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.09.011 · Cited by 93
Self-citationComparing Risk Scores in the Prediction of Coronary and Cardiovascular Deaths
Blaha, M. J., Whelton, S. P., Rifai, M. A., Dardari, Z., Shaw, L. J., Al-Mallah, M. H., Matsushita, K., Rozanski, A., Rumberger, J. A., Berman, D. S., et al. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.12.010 · Cited by 93
Metadata
- Authors
- Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., Deaton, C., Ebrahim, S., Fisher, M., Germano, G., Hobbs, R., Hoes, A., Karadeniz, S., Mezzani, A., Prescott, E., Ryden, L., Scherer, M., Syvänne, M., Scholte Op Reimer, W. J. M., Vrints, C., Wood, D., Zamorano, J. L., Zannad, F., guidelines:, O. E. W. C. T. P. O. T., Cooney, M. T., ESC Committee for Practice Guidelines (CPG):, Bax, J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Ž., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Reviewers:, D., Funck-Brentano, C., Sirnes, P. A., Aboyans, V., Ezquerra, E. A., Baigent, C., Brotons, C., Burell, G., Ceriello, A., De Sutter, J., Deckers, J., Del Prato, S., Diener, H.-C., Fitzsimons, D., Fras, Z., Hambrecht, R., Jankowski, P., Keil, U., Kirby, M., Larsen, M. L., Mancia, G., Manolis, A. J., McMurray, J., Pająk, A., Parkhomenko, A., Rallidis, L., Rigo, F., Rocha, E., Ruilope, L. M., van der Velde, E., Vanuzzo, D., Viigimaa, M., Volpe, M., Wiklund, O., & Wolpert, C.
- Affiliations
- Linnaeus University (SE)
- 1 Societies: 1European Society of Cardiology (ESC)
- European Society of Cardiology (FR)
- European Society of Hypertension (IT)
- 5 European Society of Hypertension (ESH)
- European Association for the Study of Diabetes (DE)
- 6 European Association for the Study of Diabetes (EASD)
- European Heart Network (BE)
- Corresponding author
- Authors/Task Force Members:
- ORCID
- Graham, Ian
- Albus, Christian
- Benlian, Pascale
- Ebrahim, Shah
- Hobbs, Richard
- Karadeniz, Sehnaz
- Mezzani, Alessandro
- Prescott, Eva
- Scherer, Martin
- Wood, David
- Zannad, Faiez
- Cooney, Marie Therese
- Bax, Jeroen
- Ceconi, Claudio
- Hasdai, David
- Kirchhof, Paulus
- Knuuti, Juhani
- Kolh, Philippe
- McDonagh, Theresa
- Popescu, Bogdan A.
- Torbicki, Adam
- Vahanian, Alec
- Windecker, Stephan
- Aboyans, Victor
- Baigent, Colin
- Brotons, Carlos
- Ceriello, Antonio
- Fitzsimons, Donna
- Fras, Zlatko
- Hambrecht, Rainer
- Jankowski, Piotr
- Kirby, Mike
- Mancia, Giuseppe
- Manolis, Athanasios J.
- McMurray, John
- Parkhomenko, Alexander
- Rigo, Fausto
- Rocha, Evangelista
- Ruilope, Luis Miguel
- Vanuzzo, Diego
- Viigimaa, Margus
- Volpe, Massimo
- Wiklund, Olov
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-03
- Volume
- 33
- Issue
- 13
- Pages
- 1635-1701
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3021842026
- Cited by
- 8,490
- References
- 868
- Citations by year
- 2026: 29 · 2025: 94 · 2024: 237 · 2023: 331 · 2022: 409 · 2021: 740 · 2020: 895 · 2019: 837 · 2018: 799 · 2017: 802 · 2016: 694 · 2015: 684 · 2014: 693 · 2013: 561 · 2012: 329
- FWCI
- 700.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Funders
- Wellcome Trust (084674)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Keywords
- cardiovascular disease prevention, cardiovascular risk management, primary prevention, secondary prevention, cardiovascular risk assessment
- MeSH terms
- Smoking Prevention, Adult, Aged, Antihypertensive Agents, Blood Pressure, Cardiology, Cardiovascular Agents, Cardiovascular Diseases, Chronic Disease, Delivery of Health Care, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diagnostic Imaging, Diet, Drug Combinations, Female, Health Promotion, Hospitalization, Humans, Hypercholesterolemia, Hypertension, Life Style, Lipids, Male, Middle Aged, Obesity, Physician's Role, Primary Health Care, Prognosis, Self Care, Smoking, Socioeconomic Factors, Stress, Psychological, Biomarkers, Exercise, Smoking Cessation, Risk Assessment, Patient Selection, Evidence-Based Medicine, Nurse's Role, Risk Reduction Behavior, Early Diagnosis, Medication Adherence, Electronic Health Records, General Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review